## CURRICULUM VITAE

**Peter William Nickerson** Distinguished Professor of Internal Medicine and Immunology

***Under Graduate Education:***

1. University of Manitoba BSc (Med) 1986 Biochemistry
2. University of Manitoba MD 1986 Medicine

***Post Graduate Studies:***

1. Rotating Medicine Internship University of Manitoba Focus on Internal Medicine

(1986-1987)

* Internal Medicine Fellowship University of Manitoba Topic: General Internal Medicine

(1987-1990) (Program Director: Dr. W Coke)

* Nephrology Fellowship University of Manitoba Topic: Nephrology

(1990-1991) (Program Director: Dr. DN Rush)

* Transplant Research Fellowship Harvard Medical School Topic: Transplant Immunogenetics

(1991-1995) (Beth Israel Hospital) (Supervisor: Dr. TB Strom)

***Academic Appointments:***

* 2015 - present **Vice Dean (Research), Rady Faculty of Health Sciences, University of Manitoba**
* 2010 - 2015 Associate Dean (Research), Max Rady College of Medicine
* 2016 - present **Distinguished Professor of Internal Medicine and Immunology**
* 2009 - present **Flynn Family Chair in Renal Transplantation**
* 2005 - 2016 Professor of Internal Medicine and Immunology
* 1999 - 2005 Associate Professor of Internal Medicine
* 1995 - 2005 Assistant Professor of Immunology
* 1995 - 1999 Assistant Professor of Internal Medicine

***Clinical/Administrative Appointments:***

* 2014 - present **Medical Director, Transplant Manitoba, Shared Health**
* 2009 - present **Medical Advisor (Organ Transplantation), Canadian Blood Services**
* 2001 - present  **Medical Director, Platelet Immunology Laboratory, Canadian Blood Services**
* 2005 - 2010 Medical Director, Transplant Manitoba – Gift of Life Program
* 1999 - 2004 Director, Immunology Laboratory Sub-program, Winnipeg Regional Health Authority
* 1998 - present **Medical Consultant, Transplant Immunology Laboratory, Shared Health**
* 1995 - present  **Clinical Nephrologist, Health Sciences Centre, Shared Health**

***Awards:***

* Dr. John Bowman Memorial Award (2021) Winnipeg Rh Institute Foundation, University of Manitoba
* Life-Time Achievement Award (2020) Canadian Society of Transplantation
* Rose Payne Distinguished Scientist Award (2020) Am Society of Histocompatibility and Immunogenetics
* Medal for Research Excellence (2018) Kidney Foundation of Canada
* Paul I. Terasaki Clinical Science Award (2016) Am Society of Histocompatibility and Immunogenetics
* Clinical Science Established Investigator Award (2016) American Society of Transplantation
* Scholastic Award (2014) Doctors Manitoba
* Fellow Canadian Academy of Health Sciences (2012) Canadian Academy of Health Sciences
* Dr. John B. Dossetor Research Award (2012) Kidney Foundation of Canada
* Distinguished Service Award (2009) Am Society of Histocompatibility and Immunogenetics
* Rh Award for Clinical Research (2002) University of Manitoba
* International Young Investigator Award (May 1997) American Society of Transplant Physicians
* Scholarship Award (1997 - 2002) Medical Research Council of Canada
* Young Investigator Award (May 1995) American Society of Transplant Physicians
* Fellowship Award (1991 - 1995) Medical Research Council of Canada

***Research Activities:***

Areas of Research Focus:

**Transplant Immunology:**

* Focus on the role of HLA matching and HLA antibody in both acute and chronic rejection.
* Evaluation of clinical and pre-transplant factors that determine clinical outcome in renal transplantation.
* Clinical trials to assess mechanisms of cellular and antibody mediated rejection in kidney allografts.

**Non-invasive Diagnostics:**

* As a founding member of the Manitoba Centre for Proteomics studies are being conducted to identify urine and serum proteins unique to renal allograft rejection. These studies may reveal novel therapeutic targets for drug design, in addition to providing non-invasive diagnostic tools.

**Health Care System Design:**

* Using business and engineering tools (Strategy Maps and Balance Scorecards, Process Mapping) to develop novel solutions to enhancing access to transplant and improve outcomes for patients with end-organ failure.
* Development of organ allocation policy based on translational research to enhance equitable access to organ transplants.
* Standardization of laboratory diagnostics policy in Canada to enhance transplant outcomes.

**Publications:** Scopus (13 October 2021): Documents – **188** Citations – **13,900**

**Research Papers (Peer-Reviewed):**

1. Cuvelier S, Van Caeseele P, Kadatz M, Peterson K, Sun S, Dodd N, Werestiuk K, Koulack J, **Nickerson PW**, Ho J. Expanding the deceased donor pool in Manitoba using hepatitis C viremic donors: program report. Can J Kidney Health Dis, accepted 11 June 2021.
2. Lang S, Sharma A, Foster B, Gibson IW, Ho J, **Nickerson P**, Wishart D, Blydt-Hansen T. Age and sex determine conversion from immediate-release to extended-release tacrolimus in a multi-center cohort of Canadian pediatric renal transplant recipients. Pediatric Transplant (2021):25:e13959.
3. Blydt-Hansen T, Sharma A, Gibson IW, Wiebe C, Sharma AP, Langlois V, Teoh CW, Rush D, **Nickerson P**, Wishart D, Ho J. Validity and utility of urinary CXCL10/Cr immune monitoring in pediatric kidney transplant recipients. Am J Transplant. (2021) 21(4):1545-1555.
4. **Nickerson PW**, Balshaw R, Wiebe C, Ho J, Gibson IW, Bridges ND, Rush DN, Heeger PS. A non-inferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation. Am J Transplant (2021) 21(4):1503-1512.
5. Hoffman AJ, Gibson IW, Ho J, **Nickerson P**, Rush D, Sharma A, Wishart D, Blydt-Hansen TD. Early surveillance biopsy utilization and management of pediatric renal allograft acute T cell-mediated rejection in Canadian centers: Observations from the PROBE multicenter cohort study. Pediatr Transplant (2021) 25:e13870
6. Irish W, **Nickerson P**, Astor BC, Chong E, Wiebe C, Morerso F, Seron D, Crespo M, Ganche L, Djamali A. Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation. Transplantation (2021) 105(3):648-659
7. Navarrete M, Wilkins JA, Chan FV, Ye B, **Nickerson P**, Ho J. [Phospholipase A2 group XV activity during cardiopulmonary bypass surgery.](https://pubmed-ncbi-nlm-nih-gov.uml.idm.oclc.org/33307060/) Clin Biochem (2021) 88:49-55
8. Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E, Grafals M, Pomfret E, **Nickerson P**, Cooper JE. Adequate tacrolimus exposure modulates the impact of HLA Class II molecular mismatch: A validation study in an American cohort. Am J Transplant (2021) 21(1):322-328
9. Degner KR, Parajuli S, Aziz F, Garg N, Mohamed M, Mandelbrot DA, Panzer SE, Wilson NA, Reese SR, Van Hyfte K, Zhong W, Hidalgo LG, **Nickerson P**, Djamali A. Modest improvement in refractory antibody-mediated rejection after prolonged treatment. Kid Int Rep (2021) 6(5):1397-1401
10. Gu Y, Koh RWK, Lai ML, Pochinco D, Teo RZC, Chan M, Murali TM, Liew CW, Wong YH, Gascoigne NRJ, Wood KJ, Lescar J, **Nickerson P**, MacAry PA, Vathsala A. Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation. Scientific Reports (2020) 10(1):18397.
11. Navarrete M, Korkmaz B, Guarino C, Lesner A, Lao Y, Ho J, **Nickerson P**, Wilkins JA. Activity-based protein profiling guided identification of urine proteinase 3 activity in subclinical rejection after renal transplantation. Clinical Proteomics (2020) 17(1):Article 23
12. Zheng K, Sutherland S, Cardinal P, Meade M, Landriault A, Vanderspank-Wright B, Valiani S, Shemie S, Appleby A, Keenan S, Weiss M, Werestiuk K, Kramer AH, Kawchuk J, Beed S, Dhanani S, Pagliarello G, Chasse M, Lotherington K, Gatien M, Parsons K, Chandler C, **Nickerson P**, Kutsogiannis J, Sarti AJ. Patient-centered and family-centered care of the critically ill patients who are potential organ donors: a qualitative study protocol of family member perspectives. BMJ Open (2020) 10(6):e037527
13. Dai H, Lan P, Zhao D, Abou-Daya K, Liu W, Chen W, Friday AJ, Williams AL, Sun T, Chen W, Mortin-Toth S, Danska JS, Wiebe C**, Nickerson P**, Li T, Mathews LR, Turnquist HR, Nicotra ML, Gingras S, Takayama E, Kubagawa H, Shlomchik MJ, Oberbarnscheidt MH, Li XC, Lakkis FG. PIRs mediate innate myeloid cell memory to nonself MHC molecules. Science (2020) 368(6495):1122-1127
14. Wiebe C, Rush D, Ian G, Pochinco D, Birk P, Goldberg A, Blydt-Hansen T, Karpinski M, Shaw J, Ho J, **Nickerson P**. Evidence for the alloimmune basis and prognostic significance of borderline T-cell mediated rejection. Am J Transplant. (2020) 20(9):2499-2508.
15. Kramer AH, Holliday K, Keenan S, Isac G, Kutsogiannis DJ, Knetemen NM, Robertson A, **Nickerson P**, Tibbles LA. Donation after circulatory determination of death in western Canada: a multicenter study of donor characteristics and critical care practices. Canadian Journal of Anesthesia (2020) 67(5):521-531.
16. Handschin J, Hirt-Minkowski P, Honger G, Mitrovic S, Savic Prince A, Ho J, **Nickerson P**, Schaub S. Technical considerations and confounders for urine CXCL-10 chemokine measurement. Transplantation Direct (2020) 6:e519.
17. Rampersad C, Shaw J, Gibson IW, Wiebe C, Rush DN, **Nickerson PW**, Ho J. Early antibody-mediated kidney transplant rejection associated with anti-vimentin antibodies: A case report. Am J Kid Disease (2020) 75:138-143.
18. Shaw J, Gibson IW, Wiebe C, Houston DS, Koulack J, Rush D, **Nickerson P**, Ho J. Hyperacute antibody-mediated rejection associated with red blood cell antibodies. Transplantation Direct (2019) 5:e477 DOI:10.1097/TXD.0000000000000925.
19. Ho J, Sharma A, Kroeker K, Carroll R, De Serres S, Gibson IW, Hirt-Minkowski P, Jevnikar A, Kim SJ, Knoll G, Rush DN, Wiebe C, **Nickerson P**. Multicentre randomized controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. BMJ Open (2019) 9(4):e024908.
20. Cockfield SM, Wilson S, Campbell P, Cantarovich M, Gangji A, Houde I, Jevnikar AM, Keough-Ryan T, Monroy-Cuadros M, **Nickerson PW**, Paquet MR, Prasad GVR, Senecal L, Shoker A, Wolff JL, Howell J, Schwartz J, Rush DN. Comparison of the effects of standard versus low-dose prolonged release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts. Am J Transplantation (2019) 19:1730-1744
21. Wiebe C, Kosmoliaptsis V, Pochinco D, Gibson I, Ho J, Birk P, Goldberg A, Karpinski M, Shaw J, Rush D, **Nickerson P**. HLA DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. Am J Transplantation (2019) 19:1708-1719.
22. Mincham CM, Gibson IW, Sharma A, Wiebe C, Mandal R, Rush D, **Nickerson P**, Ho J, Wishart DS, Blydt-Hansen TD. Evolution of renal function and urinary biomarker indicators of inflammation on serial kidney biopsies in pediatric kidney transplant recipients with and without rejection. Pediatric Transplantation (2018) 22(5) e13202 DOI:10.1111/petr.13202.
23. Wiebe C, Kosmoliaptsis V, Pochinco D, Taylor C, **Nickerson P**. A comparison of HLA molecular mismatch methods to determine HLA immunogenicity. Transplantation (2018) 102:1338-1343.
24. Faddoul G, Nadkarni GN, Bridges N, Goebel J, Hricik DE, Formica R, Menon MC, Morrison Y, Murphy B, Newell K, **Nickerson P**, Poggio E, Rush D, Heeger PS. Analysis of biomarkers within the initial 2 years post-transplant and 5-year kidney transplant outcomes: Results from the Clinical Trials in Organ Transplantation-17. Transplantation (2018) 102:673-680.
25. Ho J, Schaub S, Wiebe C, Gao A, Wehmeier C, Koller MT, Hirsch HH, Hopfer H, **Nickerson P**, Hirt-Minkowski P. Urinary CXCL10 chemokine is associated with alloimmune and virus compartment-specific renal allograft inflammation. Transplantation (2018) 102:521-529. **Highlighted on journal cover and accompanied by editorial**.
26. Gareau AJ, Wiebe C, Pochinco D, Gibson IW, Ho J, Rush DN, **Nickerson PW**. Pre-transplant AT1R antibodies correlate with early allograft rejection. Transplant Immunology (2018) 46:29-35.
27. Blydt-Hansen T, Sharma A, Gibson I, Wishart D, Mandal R, Ho J, **Nickerson P**, Rush D. Urinary metabolomics for non-invasive detection of antibody-mediated rejection in children after kidney transplantation. Transplantation (2017) 101:2553-2561
28. Wiebe C, Rush D, Nevins T, Birk P, Blydt-Hansen T, Gibson I, Goldberg A, Ho J, Karpinski M, Pochinco D, Sharma A, Storsley L, Matas A, **Nickerson P**. Class II eplet mismatch modulates tacrolimus levels required to prevent DSA development. J Am Soc Nephrol (2017) 28:3353-3362
29. Larcombe LA, Shafer LA, **Nickerson PW**, Lodge AM, Brown JS, Miligan LC, Pochinco D, Beaudin L, Arundel B, Wong J, Dantouze J, Denechezhe L, Orr PH. HLA-A, B, DRB1, DQA1, DQB1 alleles and haplotype frequencies in Dene and Cree cohorts in Manitoba, Canada. Human Immunology (2017) 78:401-411
30. Wiebe C, Gareau A, Pochinco D, Gibson I, Ho J, Birk P, Blydt-Hansen T, Karpinski M, Goldberg A, Storsley L, Rush D, **Nickerson P**. Evaluation of C1q status and titre of *de novo* donor specific antibodies as predictors of allograft outcome. Am J Transplantation (2017) 17:703-711
31. Hirt-Minkowski P, Rush DN, Gao A, Hopfer H, Wiebe C, **Nickerson PW**, Schaub S, Ho J. Six-month urinary CCL2 and CXCL10 levels predict long-term renal allograft outcome. Transplantation (2016) 100:1988-1996. **Accompanied by editorial.**
32. Ho J, Sharma A, Mandal R, Wishart D, Wiebe C, Storsley L, Karpinski M, Gibson IW, **Nickerson PW**, Rush D. Detecting renal allograft inflammation using quantitative urine metabolomics and CXCL10. Transplantation (2016) 2:e78 (doi:10.1097/txd.0000000000000589)
33. Rose C, **Nickerson P**, Delmonico F, Randhawa G, Gill J, Gill JS. Estimation of potential deceased organ donors in Canada. Transplantation (2016) 100:1558-1563
34. Ho J, Rush DN, Krokhin O, Antonovici M, Gao A, Bestland J, Wiebe C, Hiebert B, Rigatto C, Gibson IW, Wilkins JA, **Nickerson PW**. Elevated urinary matrix metalloproteinase-7 detects underlying renal allograft inflammation and injury. Transplantation (2016) 100:648-654
35. Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, Visentin J, Bachelet T, Morelon E, **Nickerson P**, Merville P, Taupin JL, Couzi L. Non-complement-binding *de novo* donor-specific anti-HLA antibodies and kidney allograft survival. J Am Soc Nephrol (2016) 27:615-625
36. Tinckam K, Liwski R, Pochinco D, Mousseau M, Grattan A, **Nickerson P**, Campbell T. cPRA increases with DQA, DPA and DPB unacceptable antigens in the Canadian cPRA calculator. Am J Transplantation (2015) 15:3194-3201
37. Hricik DE, Augustine J, **Nickerson P**, Formica RN, Poggio E, Rush D, Newel K, Goebel J, Gibson IW, Fairchild RL, Spain K, Ikle D, Bridges N, Heeger PS. Interferon gamma ELISPOT testing as a risk-stratifying biomarker for kidney transplant injury: results from the CTOT-01 multicenter study. Am J Transplantation (2015) 15:3166-3173
38. Larcombe L, Mookherjee N, Slater J, Slivinski C, Dantouze J, Singer M, Whaley C, Denechezhe L, Matyas S, Decter K, Turner-Brannen E, Ramsey C, **Nickerson P**, Orr P. Vitamin D, serum 25(OH)D, LL-37 and polymorphisms in a Canadian First Nation population with endemic tuberculosis. International Journal of Circumpolar Health (2015) 74:28952
39. Hricik DE, Formica RN, **Nickerson P**, Rush D, Fairchild RL, Poggio ED, Gibson IW, Wiebe C, Tinckam K, Bunnapradist S, Samaniego-Picota M, Brennan DC, Schroppel B, Gaber O, Armstrong B, Ikle D, Diope H, Bridges ND, Heeger PS (for the CTOT-09 consortium). Adverse outcomes of Tacrolimus withdrawal in low-risk, immunologically quiescent kidney transplant recipients: results of the CTOT-09 Trial. J Am Soc Nephrol (2015) 26:3114-3122. **Accompanied by editorial**.
40. Wiebe C, Gibson IW, Blydt-Hansen T, Pochinco D, Birk PE, Ho J, Karpinski M, Goldberg A, Storsley L, Rush DN, **Nickerson PW**. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplantation (2015) 15:2921-2930
41. Hirt-Minkowski P, Ho J, Gao A, Amico P, Koller MT, Hopfer H, Rush DN, **Nickerson PW**, Schaub S. Prediction of long-term renal allograft outcome by early urinary CXCL10 chemokine levels. Transplantation Direct (2015) 1:e31
42. Wiebe C, Nevins TE, Robiner WN, Thomas W, Matas AJ, **Nickerson PW**. The synergistic effect of Class II HLA epitope-mismatch and non-adherence on acute rejection and graft survival. Am J Transplantation (2015) 15:2197-2202. **Accompanied by editorial**.
43. Cole EH, **Nickerson P**, Campbell P, Yetzer K, Lahaie N, Zaltzman J, Gill JS. The Canadian Kidney Paired Donation Program: a national program to increase living donor transplantation. Transplantation (2015) 99:985-990.
44. Bueti J, Rush D, Tangri N, Mandelzweig K, Xu Y, Hiebert B, Sood MM, Komenda P, **Nickerson P**, Rigatto C. Effect of time on dialysis and renal transplantation on endothelial function: A longitudinal analysis. Transplantation (2014) 98:1060-1068.
45. Ho J, Wiebe C, Gibson IW, Hombach-Klonish S, Gao A, Rigatto C, Karpinski M, Storsley L, **Nickerson PW**, Rush D. Elevated Urinary CCL2:Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Transplantation (2014) 98:39-46
46. Wiebe C, Pochinco D, Blydt-Hansen T, Ho J, Birk P, Karpinski M, Goldberg A, Storsley L, Gibson I, Rush D, **Nickerson P**. Class II HLA epitope matching – A strategy to minimize de novo donor specific antibody development and improve outcomes. Am J Transplantation (2013) 13:3114-3122. **Accompanied by editorial.**
47. Hricik DE, **Nickerson P**, Formica R, Poggio E, Rush D, Newell KA, Goebel J, Gibson IW, Fairchild R, Riggs M, Ilke D, Bridges ND, Heeger PS (for the CTOT-01 consortium). Multicentre validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplantation (2013) 13:2634-2644. **Accompanied by editorial.**
48. Slater J, Larcombe L, Green C, Slivinski C, Singer M, Denechezhe L, Whaley C, **Nickerson P**, Orr P. Dietary intake of vitamin D in a northern Canadian Dene First Nation community. International J Circumpolar Health (2013) 72:Suppl 1 Article Number 20723.
49. Braun K, Larcombe L, Orr P, **Nickerson P**, Wolfe J, Sharma M. Killer immunoglobulin-like receptor (KIR) centromeric –AA haplotype is associated with ethnicity and tuberculosis disease in a Canadian First Nation Cohort. PLoS ONE (2013) 8:e67842.
50. Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, Lunz J, Mohanakumar T, **Nickerson P**, Tamber AR, Zeevi A, Heeger PS, Gjertson D. Comprehensive Assessment and Standardization of Solid Phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplantation (2013) 13:1859-1870. **Highlighted on the journal cover.**
51. Ho J, Wiebe C, Rush DN, Rigatto C, Storsley L, Karpinski M, Ang G, Gibson IW, **Nickerson PW**. Increased urinary CCL2:Cr ratio at 6 months is associated with late renal allograft loss. Transplantation (2013) 95:595-602. **Highlighted by the journal with an e-video.**
52. Saw CL, Hannach B, Petrazsko T, **Nickerson P**. Blood donors implicated in transfusion-related acute lung injury with patient-specific HLA antibodies are more broadly sensitized to HLA antigens compared to other blood donors. Transfusion (2013) 53:518-525.
53. Navarrete M, Ho J, Krokhin O, Ezzati P, Rigatto C, Reslerova M, Rush DN, **Nickerson P**, Wilkins JA. Proteomic characterization of serine hydrolase activity and composition in normal urine. Clinical Proteomics (2013) 10:17
54. Larcombe L, Mookherjee N, Slivinski C, Slater J, Singer M, Whaley C, Denechezhe L, Matyas S, Turner-Brannen E, **Nickerson P**, Orr P. Vitamin D in a Northern Canadian First Nation Population: dietary intake, serum concentrations and functional gene polymorphisms. PLoS ONE (2012) 7:e49872.
55. Larcombe L, Orr P, Turner-Brannen E, Slivinski CR, **Nickerson PW**, Mookherjee N. Effect of Vitamin D supplementation on Mycobacterium tuberculosis-induced innate immune responses in a Canadian Dene first nations cohort. PLoS ONE (2012) 7:e40692.
56. Rosenblum AM, Li AH, Roels L, Stewart B, Prakash V, Beitel J, Young K, Shemie S, **Nickerson P**, Garg AX. Worldwide variability in deceased organ donor registries. Transpl Int (2012) 25: 801-811.
57. Hirt-Minkowski P, Patrizia A, Ho J, Gao A, Bestland J, Hopfer H, Steiger J, Dickenmann M, Burkhalter F, Rush D, **Nickerson P**, Schaub S. Detection of clinical and subclinical tubule-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplantation (2012) 12:1811-1823.
58. Wiebe C, Gibson I, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, **Nickerson PW**. Evolution and clinical pathologic correlations of de novo donor specific antibody post kidney transplant. Am J Transplantation (2012) 12:1157-1167. **Highlighted on journal cover and accompanied by editorial**.
59. Ho J, Reslerova M, Gali B, **Nickerson PW**, Rush DN, Sood MM, Bueti J, Komenda P, Pascoe E, Arora RC, Rigatto C. Serum creatinine measurement immediately after cardiac surgery and prediction of acute kidney injury. Am J Kidney Disease (2012) 59:196-201.
60. Ho J, Reslerova M, Gali B, Gao A, Bestland J, Rush DN, **Nickerson PW**,Rigatto C. Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary bypass. Clin J Am Soc Nephrol (2011) 6:2340-2346. **Accompanied by editorial.**
61. Ho J, Rush D, Karpinski M, Storsley L, Gibson I, Bestland J, Gao A, Stefura W, HayGlass K, **Nickerson PW**. Validation of urinary CXCL10 as a biomarker of borderline, subclinical and clinical tubulitis. Transplantation (2011) 92:878-882. **Highlighted by Nature Reviews Nephrology, Research Highlights in Brief**.
62. Shemie SD, Hornby L, Chandler J, **Nickerson P**, Burkell J. Lifetime probabilities of needing an organ transplant versus donating an organ after death. Am J Transplantation (2011) 11:2085-2095.
63. Rempel JD, Hawkins K, Lande E, **Nickerson P**. The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas. Eur J Hum Genet (2011) 19:1276-1280.
64. Larcombe L, **Nickerson P**, Singer M, Robson R, Dantouze J, McKay L, Orr P. Housing conditions in 2 Canadian First Nations communities. Int J Circumpolar Health (2011) 70:141-153.
65. Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C, Martin S, **Nickerson P**, Peltekian K, Ross H, Waddell TK, West L, Anderson D, Freedman J, Hume H. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfusion Med. Reviews (2010) Suppl 1 24(1) pp S7-S27
66. Saw CL, Szykoluk K, Curtis BR, Zelcer S, Eckert K, Forrest D, **Nickerson P**, Petraszko T, Goldman M. Two cases of platelet transfusion refractoriness associated with anti-CD36. Transfusion (2010) 50:2638-2642
67. Storsley LJ, Young A, Rush DN, **Nickerson PW**, Ho J, Suon V, Karpinski M. Long-term medical outcomes among Aboriginal living kidney donors. Transplantation (2010) 90:401-406
68. Ho J, Rush DN, Gibson IW, Karpinski M, Storsley L, Bestland J, Stefura W, HayGlass K, **Nickerson PW**. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation (2010) 90:394-400
69. Rush D, Cockfield SM, **Nickerson PW**, Arlen D, Boucher A, Busque S, Girardin C, Knoll G, Lachance J-G, Landsberg D, Shapiro RJ, Shoker A, Yilmaz S. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving TAC and MMF. Transplantation (2009) 88:897-903
70. Schaub S, **Nickerson P**, Rush D, Mayr M, Hess C, Golian M, Stefura W, Hayglass K. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplantation (2009) 9:1347-1353
71. Ho J, Lucy M, Krokhin O, HayGlass K, Pascoe E, Darroch G, Rush D, **Nickerson P**, Rigatto C, Reslerova M. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case control study. Am J Kidney Disease (2009) 53:584-595. **Accompanied by editorial.**
72. Larcombe LA, Orr PH, Lodge AM, Brown JS, Dembinski IJ, Milligan LC, Larcombe EA, Martin BD, **Nickerson PW**. Functional gene polymorphisms in Canadian Aboriginal populations with high rates of tuberculosis. Journal of Infectious Diseases (2008) 198:1175-1179
73. Stinson M, Douville R, Lissitsyn Y, Blanchard M, Stefura W, Simons E, Becker A, **Nickerson P**, Coombs K, HayGlass K. Quantification of human chemokine production in TLR-stimulated and antigen-specific recall responses. Methods Mol Med (2008) 138:121-131
74. Schaub S, Mayr M, Honger G, Bestland J, Steiger J, Regeniter A, Mihatsch MJ, Wilkins JA, Rush D, **Nickerson P**. Detection of subclinical tubular injury after renal transplantation: Comparison of urine protein analysis with allograft histopathology. Transplantation (2007) 84:104-112
75. Aborsangaya KB, Dembinski I, Khatkar S, Alphonse MP, **Nickerson P**, Rempel JD. The impact of Aboriginal ethnicity on HCV Core induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology (2007) 45:623-630
76. Singal RK, Docking LM, Girling LG, Graham MR, **Nickerson PW**, McManus BM, Magil AB, Walker EK, Warrian RK, Cheang MS, Mutch WA. Biologically variable bypass reduces enzymuria after deep hypothermic circulatory arrest. Ann Thorac Surg (2006) 82:1480-1488
77. Lazaro AM, Cao K, Masaberg C, Steiner NK, Xiao Y, Tu B, Turner V, **Nickerson P**, Stoll S, Schall C, Valdez R, Ng J, Hartzman RJ, Hurley CK. Twenty-three novel HLA-B alleles identified during intermediate-resolution testing. Tissue Antigens (2006) 68:245-248
78. McLaughlin K, Manns B, **Nickerson P**. The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective. Transplantation (2006) 81:1278-1284
79. Oen K, Robinson DB, **Nickerson P**, Katz SJ, Cheang SJ, Peschken CA, Canvin JMG, Hitchon CA, Schroeder ML, El-Gabalawy H. Familial Seropositive Rheumatoid Arthritis in North American Native Families: Effects of shared epitopes and cytokine genotypes. J Rheumatol (2005) 32:983-991
80. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, **Nickerson P**, Reed M. Cytokine Genotypes Correlate with Pain and Radiologically Defined Joint Damage in Patients with Juvenile Rheumatoid Arthritis. Rheumatology (Oxford) (2005) 44:1115-1121
81. Tinckam K, Rush D, Hutchinson I, Dembinski I, Pravica V, Jeffery J, **Nickerson P**. The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and 6-month renal allograft pathology. Transplantation (2005) 79:836-841
82. Cantor M, **Nickerson P**, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterology (2005) 100:1134-1142
83. Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, **Nickerson P**. Proteomic-based identification of cleaved urinary 2-microglobulin as a potential maker for acute tubular injury in renal allografts. Am. J Transplantation (2005) 5:729-738
84. Larcombe LA, Rempel J, Dembinski I, Tinckam K, Rigatto C, **Nickerson P**. Differential cytokine genotype frequencies among Canadian Aboriginal and Caucasian populations. Genes and Immunity (2005) 6:140-144
85. Larcombe LA, **Nickerson P**, Hoppa RD, Matheson C. Detection of a single nucleotide polymorphism in the IL-6 promoter region of ancient nuclear DNA. Infection, Genetics and Evolution (2005) 5:117-122
86. Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, **Nickerson P**. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrology (2004) 15:818-824
87. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, Karpinski M, Jeffery J, **Nickerson P**. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrology (2004) 15:219-227
88. Schaub S, Wilkins J, Sangster K, Weiler T, Rush D, **Nickerson P**. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Kidney International (2004) 65:323-332
89. Jeffery JR, Leslie WD, Karpinski M, **Nickerson PW**, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: A randomized prospective trial of calcitriol versus alendronate. Transplantation (2003) 76:1498-502
90. Grimm PC, **Nickerson P**, Gough J, McKenna R, Stern E, Jeffery J, Rush D. Computerized image analysis of Sirius Red stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrology (2003) 14:1662-1668
91. Karpinski M, Rush D, Jeffery J, Pochinco D, Milley D, **Nickerson P**. Heightened peripheral blood lymphocyte CD69 expression is neither sensitive nor specific as a non-invasive diagnostic test for renal allograft rejection. J Am Soc Nephrology (2003) 14:226-233
92. Gough J, Rush D, Jeffery J, **Nickerson P**, McKenna R, Solez K, Trpkov K. Reproducibility of the Banff Schema in Reporting Protocol Biopsies of Stable Renal Allografts. Nephrol Dial Transplant (2002) 17:1081-1084
93. Somorjai RL, Dolenko B, Nikulin A, **Nickerson P**, Rush D, Shaw A, Glogowski M, Rendell J, Deslauriers R. Distinguishing normal from rejecting renal allografts: Application of a three-stage classification strategy to MR and IR spectra of urine. Vibrational Spectroscopy (2002) 28:97-102
94. Johanna T.A. Meij, Farah Sheikh, Sarah K. Jimenez, **Peter W. Nickerson**, Elissavet Kardami, Peter A. Cattini. Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. AM J Physiol Heart Circ Physiol (2002) 282:H547-H555
95. Karpinski M, Rush D, Jeffery J, Dancea S, Exner M, Regele H, Pochinco D, Birk P, **Nickerson P**. Flow cytometric cross-matching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity cross-match. J Am Soc Nephrology (2001) 12:2807-2814
96. Torng S, Rigatto C, Rush DN, **Nickerson P**, Jeffery JR. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in renal transplant patients. Transplantation (2001) 72:1453-1456
97. Grimm PC, **Nickerson P**, Jeffery J, Savani RC, Gough J, McKenna RM, Stern E, Rush D. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal allograft rejection. N Eng J Med (2001) 345:93-97
98. Thorne-Tjomsland G, Hosfield T, Jamieson J, Biu B, **Nickerson P**, Gough J, Rush D, Jeffery J, McKenna R. Increased levels of Galb1-4GlcNAca2-6 sialytransferase pre-transplant predict delayed graft function in kidney transplant recipients. Transplantation (2000) 69:806-808
99. Zheng XX, Steele AW, Hancock WW, Kawamoto K, Li XC, **Nickerson PW**, Li Y, Tian Y, Strom TB. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol (1999) 163:4041-4048
100. **Nickerson P**, Jeffery J, Gough J, McKenna R, Birk P, Rush DN. The effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study. J Am Soc Nephrology (1999) 10:1801-1805
101. Grimm PC, McKenna R, **Nickerson P**, Russell M, Gough J, Godpodarek E, Liu B, Jeffery J, Rush DN. Clinical rejection is distinguished from subclinical rejection by an increased infiltration of activated macrophages. J Am Soc Nephrology (1999) 10:1582-1589
102. Rush D, **Nickerson P**, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrology (1998) 9:2129-2134
103. McKenna R, Lee K, Gough J, Jeffery J, Grimm P, Rush D, **Nickerson P**. Matching for Private or Public HLA epitopes reduces acute rejection episodes and improves 2 year renal allograft function. Transplantation (1998) 66:38-43
104. Li XC, Roy-Chaudhury P, Hancock WW, Manfro R, Zand MS, Li Y, Zheng XX, **Nickerson PW**, Steiger J, Malek TR, Strom TB. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol (1998) 161:890-896
105. **Nickerson PW**, Jeffery J, Gough J, McKenna R, Grimm P, Cheang M, Rush DN. The identification of clinical and histopathological risk factors for diminished renal function 2 years post-transplant. J Am Soc Nephrology (1998) 9:482-486
106. Steiger J, **Nickerson PW**, Hermle M, Theil G, Heim M. IFNg Receptor is not required in the effector phase of the alloimmune response. Transplantation (1998) 65:1649-1652
107. Tran HM, **Nickerson PW**, Restifo AC, Woodward MA, Patel A, Allen RD, Strom TB, O’Connell PJ. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment. J Immunol (1997) 159: 2232-2239
108. Roy-Chaudhury P, **Nickerson PW**, Manfro RC, Zheng XX, Steiger J, Li YS, Strom TB. CTLA4Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model. Transplantation (1997) 64:172-175
109. Tran HM, **Nickerson PW**, Patel A, Strom TB, Allen RDM, O’Connell PJ. Short-term suppression of the xeno-immune response with mCTLA4-Fc treatment. Xenotransplantation (1997) 4: 222-227
110. Tivol EA, Boyd SD, McKean S, Borriello F, **Nickerson P**, Strom TB, Sharpe AH. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol (1997) 158: 5091-5094
111. Zheng XX, Steele AW, Hancock WW, Stevens AC, **Nickerson PW**, Roy-Chaudhury P, Tian Y, Strom TB. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol (1997) 158: 4507-4513
112. **Nickerson PW**, Zheng XX, Steiger J, Steele AW, Steurer W, Roy-Chaudhury P, Muller W, and TB Strom. Prolonged islet allograft acceptance in the absence of IL-4 expression. Transplant Immunology (1996) 4:81-85
113. Dunussi-Jaoannopoulos K, Weinstein HJ, **Nickerson PW**, Strom TB, Burakoff SJ, Croop JM, Arceci RJ. Irradiated B7-1 transduced primary AML cells can be used as therapeutic vaccines in murine AML. Blood (1996) 87:2938-2946
114. Restifo AC, Ivis-Woodward MA, Tran HM, **Nickerson PW**, Lehnert AM, Strom TB, Chapman JR, O’Connell PJ. The potential role of xenogeneic antigen-presenting cells in T-cell co-stimulation. Xenotransplantation (1996) 3:141-148
115. Steiger J**\***, **Nickerson PW\***, Steurer W, Moscovitch-Lopatin M, and TB Strom. IL2 Knockout recipient mice reject islet cell allografts. (**\***equal contributors) J Immunol (1995) 155:489-498
116. Steurer W**\***, **Nickerson PW\***, Steele A, Steiger J, Zheng X, and TB Strom. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. (**\***equal contributors) J Immunol (1995) 155:1165-1174
117. Zheng X, Steele A, **Nickerson PW**, Steurer W, Steiger J, Strom TB. Administration of Non-Cytolytic IL-10/Fc in murine models of LPS-induced septic shock and allogeneic islet transplantation. J Immunol (1995) 154:5590-5600
118. **Nickerson PW**, Rush DN, Jeffery JR, Pochinco D, McKenna RM. High serum levels of IL-6 in renal transplant recipients with monoclonal gammopathies. Transplantation (1995) 58:382-385
119. O'Connell PJ, Pacheco-Silva A, **Nickerson PW**, Muggia RA, et al. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T-cell activation transcripts. J Immunol (1993) 150:1093-1104
120. **Nickerson PW**, Orr P, Schroeder ML, Sekla L, Johnston JB. Transfusion-Associated Trypanosoma cruzi Infection in a Non-Endemic Area. Annals of Internal Medicine (1989) 111:851-853
121. George CF, **Nickerson PW**, Hanly PJ, Millar TW, Kryger MH. Sleep apnea patients have more automobile accidents. Lancet (1987) 2 (8556):447.

**Meeting Reports (Peer-Reviewed):**

1. Issa F, Strober S, Leventhal JR, Kawai T, Sykes M, Mas V, Wood KJ, Bridges N, Welniak LA, Chandran S, Madsen JC, **Nickerson P**, Demetris AJ, Lakkis FG, Thomson AW. The fourth international workshop on clinical transplant tolerance. Am J Transplant. (2021) 21(1):21-31.
2. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell LD, Clahsen-van Groningen MC, Demetris AJ, Dragun D, Duong van Huyen J-P, Farris AB, Fogo AB, Gibson IW, Glotz D, Gueguen J, Kikic Z, Kozakowski N, Kraus E, Lefaucheur C, Liapis H, Mannon RB, Montgomery RA, Nankivell BJ, Nickeleit V, **Nickerson P**, Rabant M, Racusen L, Randhawa P, Robin B, Rosales IA, Sapir-Pichhadze R, Schinstock CA, Seron D, Singh HK, Smith RN, Stegall MD, Zeevi A, Solez K, Colvin RB, Mengel M. The Banff 2019 kidney meeting report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. (2020) 20(9):2318-2331.
3. Tambur AR, Campbell PM, Chong A, Feng S, Ford M, Gebel H, Gill R, Kelsoe G, Kosmoliaptsis V, Mannon R, Mengel M, Reed E, Wiebe C, Dijke E, Sullivan H, **Nickerson P**. Sensitization in Transplantation: Assessment of Risk (STAR) 2019 Working Group Meeting Report. Am J Transplant. (2020) 20(10):2652-2668.
4. Mannon R, Morris R, Abecassis M, Axelrod D, Bala S, Friedman G, Heeger P, Lentine K, Loupy A, Murphy B, **Nickerson P**, Sarwal M, O’Doherty I, Spear N, Karpen S. Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report. Am J Transplant. (2020) 20:1495-1502
5. Schinstock C, Mannon RB, Budde K, Chong AC, Haas M, Knechtle S, Lefaucheur C, Montgomery RA, **Nickerson P**, Tullius SG, Ahn C, Asker M, Crespo M, Chadban SJ, Feng S, Jordan SC, Man K, Mengel M, Morris RE, O’Doherty I, Ozdemir BH, Seron D, Tambur AR, Tanabe K, Taupin J-L, O’Connell PJ. Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus from the Transplant Society Working Group. Transplantation (2020) 104:911-922
6. Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, Mannon RB, Reed EF, Tinckam K, Askar M, Chandraker A, Chang PP, Colvin M, Demetris AJ, Diamond JM, Dipchand AI, Fairchild RL, Ford ML, Friedewald J, Gill RG, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine DJ, Levitsky J, Mengel M, Milford E, Newell KA, O’Leary JG, Palmer S, Randhawa P, Smith J, Snyder L, Starling RC, Sweet S, Taner T, Taylor CJ, Woodle S, Zeevi A, **Nickerson P**. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplantation (2018) 18:1604-1614.
7. Ettenger R, Albrecht R, Alloway R, Belen O, Cavaille-Coll MW, Chisholm-Burns MA, Dew MA, Fitzsimmons WE, **Nickerson P**, Thompson G, Vaidya P. Meeting Report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients. Am J Transplantation (2018) 18:564-573.
8. Haas M, Loupy A, LefaucheurC, RoufosseC, GlotzD, SeronD, NankivellBJ, HalloranPF, ColvinRB, AlachkarN, BagnascoS, BouatouY, Becker JU, CornellL, Duong van HuyenJP, GibsonI, MannonR, NaesensM, NickeleitV, **NickersonP**, SegevDL, SinghHK, StegallM, RandhawaP, RacusenL, SolezK, MengelM. The Banff 2017 Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplantation (2018) 18:293-307.
9. O’Connell PJ, Kuypers DR, Mannon R, Abecassis M, Chadban SJ, Gill JS, Murphy B, **Nickerson PW**, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tulius SG, Wong G, Woodle ES, Ascher N, Morris RE. Clinical Trials for immunosuppression in Transplantation; The case for reform and change in direction. Transplantation (2017) 101:1527-1534
10. Cantarovich M, Blydt-Hansen TD, Gill J, Tinckam K, Schiff J, Alwayn I, Bain V, Dipchand AI, Isaac D, Kim J, Lien D, Zaltzman J, Young K, **Nickerson P**. Canadian forum on combined organ transplantation. Transplantation (2016) 100:1339-1348
11. Richardson R, Connelly M, Dipchand C, Garg AX, Ghanekar A, Houde I, Johnston O, Mainra R, McCarrell R, Mueller T, **Nickerson P**, Pippy C, Storsley L, Tinckam K, Wright L, Yilmaz S, Landsberg D. Kidney paired donation protocol for participating donors 2014. Transplantation (2015) 99: S1-S88.
12. Melcher ML, Blosser CD, Baxter-Low LA, Delmonico FL, Gentry SE, Leishman R, Knoll GA, Leffell MS, Leichtman AB, Mast DA, **Nickerson PW**, Reed EF, Rees MA, Rodrigue JR, Segev DL, Serur D, Tullius SG, Zavala EY, Feng S. Dynamic Challenges Inhibiting Optimal Adoption of Kidney Paired Donation: Findings of a Consensus Conference. Am J Transplantation (2013) 13:851-860
13. Tait GD, Susal C, Gebel HM, **Nickerson PW**, Zachary AA et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 95:19-47.
14. Shemie SD, Ross H, Pagliarello J, Baker AJ, Greig PD, Brand T, Cockfield S, Keshavjee S, **Nickerson P**, Rao V, Guest C, Young K, Doig C. Organ Donor Management in Canada: Recommendations of the Forum on Medical Management to Optimize Donor Organ Potential. CMAJ (2006) 174: S13-S32
15. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, Montgomery RA, **Nickerson P**, Platt JL, Rabb H, Thistlethwaite R, Tyan D, Delmonico FL. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J Transplantation (2004) 4:1033-1041
16. Racusen L, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AG, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsiker LG, Lindblad AS, Marcussen N, Mihatsch MJ, Nadasdy T, **Nickerson P**, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Taskinen E, Trpkov K, Yamaguchi Y. The Banff 97 working classification of renal allograft pathology. Kidney International (1999) 55:713-723

**Reviews / Personal Viewpoints (Peer-Reviewed):**

1. Tambur AR, Kosmoliaptsis V, Claas FHJ, Mannon RB, **Nickerson P**, Naesens M. Significance of HLA-DQ in kidney transplantation – Time to re-evaluate HLA matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney International (2021) <https://doi.org/10.1016/j.kint.2021.06.026>
2. Wiebe C, **Nickerson PW**. More precise donor-recipient matching: the role of eplet matching. Curr Opin Nephrol Hypertens (2020) 29(6):630-635
3. **Nickerson PW**. What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation? Am J Transplant (2020) 20(S4):12-22.
4. Wiebe C, **Nickerson PW**. Human leukocyte antigen molecular mismatch to risk stratify kidney transplant recipients. Current Opinion in Organ Transplantation (2020) 25(1):8-14.
5. Navarrete M, Wilkins JA, Lao Y, Rush DN, **Nickerson PW**, Ho J. Activity-based protein profiling approaches for transplantation. Transplantation (2019) 103:1790-1798.
6. Wiebe C, **Nickerson P**. Human leukocyte antigen mismatch and precision medicine in transplantation. Current Opinion in Transplantation (2018) 23;4:500-505.
7. Wiebe C, Ho J, Gibson I, Rush D, **Nickerson P**. Carpe diem – Time to transition from empiric to precision medicine in kidney transplantation. Am J Transplantation (2018) 18(7):1615-1625.
8. Reed EF, **Nickerson PW**. The cutting edge of HLA diagnostics. Transplantation (2018) 102:13-14.
9. Nevins TE, **Nickerson PW**, Dew MA. Understanding medication non-adherence after kidney transplantation. J Am Soc Nephrology (2017) 28:2290-2301.
10. Arias M, Seron D, Herrero I, Rush DN, Wiebe C, **Nickerson PW**, Ussetti P, Rodrigo E, de Cos M-A. Subclinical antibody-mediated rejection. Transplantation (2017) 101: S1-S8.
11. Wiebe C, **Nickerson P**. Strategic use of epitope matching to improve outcomes. Transplantation (2016) 100:2048-2052.
12. Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, ……, **Nickerson P**, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A. Personal Viewpoint: Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level. Am J Transplantation (2015) 15:923-930.
13. Ho J, Rush DN, **Nickerson P**. Urinary biomarkers of renal transplant outcome. Current Opinion in Organ Transplantation (2015) 20:476-481.
14. Wiebe C, **Nickerson P**. Acceptable mismatching at the class II epitope level: The Canadian experience. Current Opinion in Organ Transplantation (2014) 19:442-446.
15. Arias M, Rush DN, Wiebe C, Gibson I, Blydt-Hansen TB, **Nickerson PW**, et al. Antibody-mediated rejection: Analyzing the risk, proposing solutions. Transplantation (2014) 98: S3-S21.
16. Mengel M, Campbell P, Gebel H, Randhawa R, Rodriguez ER, Colvin R, Conway J, Hachem R, Halloran P, Keshavjee S, **Nickerson P**, Murphy C, O’Leary J, Reeve J, Tinckam K, Reed EF. Precision diagnostics in transplantation: from bench to bedside. Am J Transplantation (2013) 13:562-568.
17. Wiebe C, **Nickerson P**. Post-transplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Current Opinion in Organ Transplantation (2013) 18:470-477.
18. Ho J, Wiebe C, Gibson IW, Rush DN, **Nickerson PW**. Immune Monitoring of Kidney Allografts. Am J Kidney Dis (2012) 60:629-640
19. **Nickerson P**. Post-transplant monitoring of renal allografts: are we there yet? Current Opinion in Immunology (2009) 21:563-568
20. **Nickerson P**. The impact of immune gene polymorphisms in kidney and liver transplantation. Clinical Lab Med. (2008) 28:455-68
21. Schaub S, Wilkins JA, **Nickerson P**. Proteomics and renal transplantation: searching for novel biomarkers and therapeutic targets. Contrib Nephrol. (2008) 160:65-75
22. Schaub S, Wilkins JA, Rush D, **Nickerson P**. Developing a tool for non-invasive monitoring of renal allografts. Expert Rev Proteomics (2006) Oct:3(5):497-509
23. Schaub S, Wilkins JA, **Nickerson P**. Proteomics in renal transplantation: opportunities and challenges. Clinical Transplantation (2004) 253-260
24. Bray RA, **Nickerson PW**, Kerman RH, Gebel HM. Evolution of HLA antibody detection technology emulating biology. Immunologic Research (2004) 29:41-54
25. Gebel H, Bray R, **Nickerson P**. Pre-transplant assessment of donor reactive HLA specific antibodies in renal transplantation: Contraindication versus risk. Am J Transplantation (2003) 3:1488-1500
26. **Nickerson P**, Jeffery J, Rush D. Long-term allograft surveillance: the role of protocol biopsies. Current Opinion in Urology (2001) 11:133-137
27. Rush D, Somorjai R, Deslauriers R, Shaw A, Jeffery J, **Nickerson P**. Subclinical rejection – a potential surrogate marker for chronic rejection – may be diagnosed by protocol biopsy or urine spectroscopy. Annals of Transplantation (2000) 5:44-49
28. Rush D, **Nickerson P**, Jeffery J. Protocol biopsies in the management of renal allograft recipients. Current Opinion in Nephrology & Hypertension (2000) 9:615-619
29. Rush D, Jeffery J, **Nickerson P**. Subclinical acute rejection: is it a cause of chronic rejection in renal transplantation? Transplantation Reviews (2000) 14:131-137
30. Rush DN, Karpinski ME, **Nickerson P**, Dancea S, Birk P, Jeffery JR. Does subclinical rejection contribute to chronic rejection in renal transplant patients? Clinical Transplantation (1999) 13:441-446.
31. Grimm PC, **Nickerson P**, Gough J, McKenna R, Jeffery J, Birk P, Rush D. Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatric Transplantation (1999) 3:257-270
32. Rush D, Grimm P, Jeffery J, Gough J, Lipman M, Birk P, McKenna R, **Nickerson P**. Predicting rejection: is early diagnosis achievable and important? Graft (1999) 2:S31-S35
33. Rush D, **Nickerson P**, Jeffery J, McKenna R, Grimm P, Gough J. Protocol biopsies in renal transplantation: Clinical necessity or research tool? Current Opinions in Nephrology and Hypertension (1998) 7:691-694
34. **Nickerson PW**, Steiger J, Zheng XX, Steele A, Steurer W, Roy-Chaudhury P, Strom TB. Manipulation of cytokine networks in transplantation: False hope or realistic opportunity for tolerance. Transplantation (1997) 63:489-494
35. Strom TB, Roy-Chaudhury P, Manfro R, Zheng XX, **Nickerson PW**, Wood K, Bushell A. The Th1/Th2 paradigm and the allograft response. Current Opinions in Immunology (1996) 8:688-693
36. **Nickerson PW**, Steurer W, Steiger J, Strom TB. In pursuit of the "Holy Grail": Allograft Tolerance. Kidney International (1994) 45: Suppl 44:S40-49
37. **Nickerson P**, Steurer W, Steiger J, Zheng X, Steele A and TB Strom. Cytokines and the Th1/Th2 paradigm in transplantation. Current Opinions in Immunology (1994) 6:757-764

**Book Chapters:**

1. Rush DN, **Nickerson PW**.  Rejection.  Oxford Textbook of Clinical Nephrology (4th edition) 2015, Chapter 283.  Eds Neil Turner, Norbert Lameire, David Goldsmith, Christopher Winearls, Jonathan Himmelfarb & Giuseppe Remuzzi.  Oxford University Press.  ISBN-13 9780199592548.
2. Thongboonkerd V, Cutillas PR, Unwin RJ, Schaub S, **Nickerson P**, Haubitz M, Mischak H, Nedelkov D, Kiernan UA, Nelson RW. Proteomics in human Urine. Proteomics of Human Body Fluids: Principles, Methods, and Applications. (2007) p225-268.
3. **Nickerson P**. Cytokines and their receptors as therapeutic targets. In 'Therapeutic Immunosuppression' (Angus W. Thomson, editor) 2001
4. **Nickerson PW**, Steiger J, Steurer W, Zheng XX, Steele AW, Roy-Chaudhury P, Strom TB. Cytokine Networks in Transplantation. In 'Transplantation Biology: Cellular and Molecular Aspects' (Tilney N, Strom TB, Paul L editors) 1996

**Editorial Comments:**

1. Wiebe C, **Nickerson PW**. Molecular mismatch – the renaissance of HLA in kidney transplantation. J Am Soc Nephrology (2020) 31(9):1922-1925.
2. Wiebe C, Tambur A, **Nickerson PW**. A call to action – the transplant recipient’s expectation of precision in transplant medicine. Am J Transplantation (2018) 18:2845-2846.
3. **Nickerson PW**, Rush DN. Begin at the beginning to prevent the end. J Am Soc Nephrology (2015) 26:1483-1485.
4. **Nickerson PW**, Rush DN. Rejection – an integrated response. Am J Transplantation (2013) 13:2239-2240.
5. **Nickerson PW**, Rush DN. Antibodies beyond HLA. Am J Transplantation (2013) 13:831-832.
6. Kokko KE, Bray RA, **Nickerson PW**, Gebel HM. Pro-inflammatory events and HLA antibodies: nothing to sneeze at. Am J. Transplantation (2009) 9:1971-2.
7. **Nickerson P**, Heeger PS. Proteomic portrayal of transplant pathologies. J Am Soc Nephrology (2009) 20:236-238.

**Letter to the Editor:**

1. Duquesnoy RJ, Gebel HM, Woodle ES, **Nickerson P**, Baxter-Lowe LA, Bray RA, Claas FHJ, Eckels DD, Friedewald JJ, Fuggle SV, Gerlach JA, Fung JJ, Kamoun M, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A. High-resolution HLA typing for sensitized patients: Advances in medicine and science require us to challenge existing paradigms. Am J Transplantation (2015) 15:2780-2781

**Active Research Support:**

**Grant Funded:**

**Nickerson P (PI)**, Wiebe C 01/01/20-31/12/24

**Paul I** **Terasaki Research Fund** (Operating Grant) **$1,000,000 US**

Validation of HLA-DR/DQ Molecular Mismatch Score as a Prognostic/Predictive Biomarker of Primary Alloimmunity

**Nickerson P (PI)** 01/12/09-30/11/24

**Flynn Family Chair, University of Manitoba** (Salary and Operating Grant) **$5,000,000 CDN** (Endowment)

Improving Access and Outcomes in Renal Transplantation

**Industry Trials:**

**Nickerson P (PI)**, Rush D (Site PI) 01/06/19-31/01/28

**CSL Behring. $366,400 US**

Interleukin 6 blockade modifying antibody-mediated graft injury and eGFR decline (IMAGINE)

**Prior Research Support:**

**Nickerson P (PI)**, Heeger P, Balshaw R09/17/20-31/08/21

**NIH** (NIAID R34AI150361 – Clinical Trial Planning Grant **$207,050 US**

Biomarker guided CNI substitution in Kidney Transplantation

**Heeger P (PI),** Hricik D, Nickerson P, Rush D, Gibson I, Formica R, Poggio E 01/09/14-31/08/21

**NIH** (NIAID U01AI063594 – CTOT Operating 2nd renewal since 2004) **$17,554,915 US**

Effects of inhibiting early inflammation in kidney transplant patients

**Ho J (PI),** Gibson I, Hirt-Minkowski P, Nickerson P, Rush D, Sharma A, Wiebe C 01/07/16-30/06/21

**CIHR** (Project Scheme Grant) **$2,664,284 CDN**

A randomized controlled effectiveness trial of urine CXCL10 chemokine monitoring post-renal transplant

**Wilkins J (PI),** Beavis, Coombs, El-Gabalawy, Ho, Krokhin, Marrie, Mookherjee, Nickerson, Slater

**Canada Foundation for Innovation**, Project (#33378) 01/07/15-30/06/20

Next generation proteomics in human biology and medicine **$1,400,000 CDN**

**Nickerson (PI)**, Gibson, Ho, Rush, Wilkins 01/04/14-31/03/19

**CIHR** (Operating Grant) **$804,160 CDN**

Chronic antibody-mediated rejection: Identification of mechanisms and diagnostic proteins

**Ho (PI)**, Gibson, Nickerson, Rigatto, Rush, Wilkins 01/04/13-31/03/18

**CIHR** (Operating Grant) **$854,358 CDN**

Identification of novel proteins as diagnostic or mechanistic targets for renal allograft inflammation

**West (PI) for the national transplant research program** 01/12/12-30/11/17

**CIHR (**Operating Grant**) $11,250,000 CDN**

The Canadian National Transplant Research Program (CNTRP)

**Blydt-Hansen (PI)**, Gibson, Ho, Mital, Nickerson, Wishart 01/09/12-31/08/17

**CIHR** (Operating Grant) **$951,777 CDN**

Non-invasive monitoring of pediatric kidney allograft injury to improve diagnosis and patient outcome

**Matas (PI),** Nickerson, Nevins, Hays, Robiner, Foster, Gaston, DiMartini, Dew 01/06/16-31/05/17

**NIH** (R34 Clinical Trial Planning Grant) **$250,000 US**

Epitope Mismatch and Medication Nonadherence

**Heeger (PI),** Nickerson, Rush, Gibson, Hricik, Formica 01/09/09-31/08/14

**NIH** (U01 – CTOT Operating 1st renewal from 2004) **$13,314,395 US**

Individualizing Therapy for Kidney and Heart Transplant Recipients (CTOT)

**Nickerson (PI)**, Saw, Wilkins 01/10/09-30/09/12

**CBS/CIHR** (Operating Grant) **$299,910 CDN**

Identification of Pathogenic Antibodies in Canadian Cases of Transfusion Related Lung Injury (TRALI)

**Orr (PI),** Larcombe, Nickerson, Ramsey, Slater 01/10/09-30/09/11

**CIHR** (Operating Grant) **$175,840 CDN**

The assessment of macrophage function in a First Nation population with a high prevalence of active and latent TB

**Wilkins (PI)**, Nickerson, Levin 15/11/11

**CFI** (Equipment Grant) **$986,682 CDN**

Integrating mass spectroscopy and protein functionality in biology and medicine

**Nickerson (PI)**, Gibson, Rush, Wilkins 01/10/01-30/09/09

**CIHR** (Operating Grant) **$969,795 CDN**

Proteomic approaches to identify novel pathways associated with renal allograft rejection

**Heeger (PI)**, Nickerson, Hricik, Newell, Formica, Goldfarb, Rush, Gibson 01/10/04-30/09/09

**NIH** (UO1 – CTOT Operating Grant) **$10,000,000 US**

Non-Invasive Methods to Predict Outcome in Human Transplantation

**Orr (PI)**, Nickerson, Larcombe 01/04/06-31/03/09

**NSA** (Operating Grant) **$400,000 CDN**

The Immunogenetic Program of First Nations and Susceptibility to Mycobacterium Tuberculosis Isolates”

**Orr (PI),** Larcombe, Nickerson, Robson, Sharma 01/10/06-30/09/08

**CIHR** (Operating Grant) **$176,941 CDN**

How the immunogenetic program and socio-economic conditions of Manitoba’s First Nations affect their response to Mycobacterium tuberculosis isolates

**Wilkins (PI)**, Beavis, Coombs, Ens, Nickerson 01/10/01-30/09/04

**CFI** (Equipment Grant) **$7,641,267 CDN**

Program in Systems Biology

**Wilkins (PI)**, Beavis, Coombs, Ens, Nickerson 01/10/01-30/09/04

**CIHR** (Collaborative Genomics Special Projects – Operating Grant) **$2,371,560 CDN**

Biomedical proteomics program: Approaches to the analysis of disease progression and pathogenesis

**Nickerson (PI),** 30/09/98-31/08/01

**NIH** (R01 Operating Grant) **$257,358 US**

PDGF and IGF and chronic allograft rejection

**Rush (PI),** Nickerson, Deslauriers, Somorjai01/07/99-30/06/01

**Kidney Foundation of Canada** (Operating Grant) **$79,920 CDN**

The role of urine MR or IR spectroscopy in the diagnosis of acute and chronic rejection

**Nickerson (PI)** 01/10/98-31/03/01

**CIHR/MHRC RPP** (Operating Grant) **$200,000 CDN**

Mechanisms of tolerance induction to islet allografts in normal and autoimmune mice

**Nickerson (PI)** 01/07/98-30/06/99

**CFI** (New Opportunities Fund – Equipment Grant) **$475,642 CDN**

Mechanisms of chronic allograft rejection and tolerance

**Nickerson (PI)** 01/07/97-30/06/02

**MRC/CIHR** (New Investigator Award - Salary) **$277,180 CDN**

Mechanisms of tolerance induction to islet allograft in normal and autoimmune mice

**Supervision of Graduate and Post-Graduate Research Personal:**

**Dr. K. Tinckam** (Internal Medicine Resident): 1998-2000

* Project: *The relative importance of cytokine gene polymorphisms in predicting early and late acute rejection and 6 month renal allograft pathology*
* Awards: 2000 Resident Research Day: Clinical Investigation Award (1st Place)

**Prowse Award:** Faculty of Medicine Award for Excellence in Clinical Research

**2000 CSCI/CSIM Award:** Top Prize Resident Research Project

* Current Post:Physician-in-Chief, Medicine, University Health Network, Toronto

**Dr. M. Karpinski** (Nephrology Fellow): 1999-2001

* Project: *The role of anti-HLA antibody in mediating acute and chronic allograft rejection.*
* Awards: 2000 Resident Research Day: Clinical Investigation Award (3rd Place)

**Prowse Award:** Faculty of Medicine Award for Excellence in Clinical Research

**2001 Canadian Society of Nephrology:** Top Prize Fellow Research Project

**2001 Canadian Society of Transplantation:** Top Prize Fellow Research Project

* Current Post: Assistant Professor, University of Manitoba

**Dr. S. Schaub** (Nephrology Fellow/ MSc (Immunology): 2002-2004

* Project: *Urine Proteomics for the Non-Invasive Diagnosis of Rejection*
* Awards:**2004 Canadian Society of Transplantation:** Top Prize Fellow Research Project
* Current Post: Transplant Nephrologist and HLA Lab Director, University of Basel, Basel, Switzerland

**K. McConnell** (MBA, Royal Rhodes University, School of Business): 2004-2005

* Project: *Specimen Transportation Plan, Diagnostic Services Manitoba (DSM)*

**Dr. L. Larcombe** (Post-Doc, Medical Microbiology): 2005-2009

* Project: *Cytokine Gene Polymorphisms in Aboriginal Populations*
* *Awards:* **2005-2007 MHRC Post-Doctoral Fellowship**
* Current Post: Associate Professor, Section of Infectious Disease, University of Manitoba

**Dr. J. Ho** (Nephrology Fellow): 2006-2008

* Project: *Urine Proteomics of Acute Kidney Injury*
* Awards: **2006-2008 Fellowship (Bristol Myers Squibb)**

**2007 Canadian Society of Nephrology:** Top Trainee Award

**2011-2014 Krescent Scholarship Salary Award**

* Current Post: Professor, Section of Nephrology, University of Manitoba

**Dr. C. Wiebe** (Nephrology Fellow/ MSc (Immunology), Royal College CIP): 2010-2014

* Project: *Evaluation of risk factors for post-transplant de novo HLA antibodies*
* Awards: **2010-2012 MHRC Clinical Fellowship,**

**2012-2014 Krescent Post Doctoral Fellowship Salary Award**

**Prowse Award:** Faculty of Medicine Award for Excellence in Clinical Research

* Current Post: Associate Professor, Section of Nephrology, University of Manitoba

**Dr. A. Gareau** (Post-Doc, Internal Medicine): 2014-2016

* Project: *Mechanisms of allo-antibody mediated microvascular inflammation*
* Current Post: Co-Director, HLA Laboratory, John Hopkins University, Baltimore

***Academic Activities:***

**Undergraduate and Graduate Teaching:**

* Immunobiology of Transplantation, Department of Immunology, Graduate Course **(1996 to present)**
* Clinical Transplantation, Department of Immunology, Graduate Course **(1996 to present)**
* Genetics of HLA and Antigen Processing, Department of Immunology, Graduate Course (1996 to 2008)
* Recombinant DNA Technology, Department of Immunology, Graduate Course (1998)
* Immunogenetics of Transplantation, Microbiology – Immunology, Undergraduate Course (1994 to 2004)

**Adjudicator:**

* Resident Research Day, Dept of Medicine, University of Manitoba (2000)
* Resident Research Day, Dept of Medicine, University of Manitoba (1998)

**Graduate and Undergraduate Committee Member:**

* **BSc (Med) Students**
* Sam (1995-1997) Dept of Medicine Supervisor: Dr G Shen
* **MSc Students**
* Liu (1995-1997) Dept of Physiology Supervisor: Dr L Murphy
* Binda (1995-1997) Dept of Medical Microbiology Supervisor: Dr J Wilkins
* Hadidi (1997- 1999) Dept of Immunology Supervisor: Dr J Gartner
* **PhD Students**
* Yanlong (1998-2000) Dept of Immunology Supervisor: Dr J Wilkins
* Lewkowich (1999-2002) Dept of Immunology Supervisor: Dr K HayGlass
* Larcombe (2001-2005) Dept of Anthropology Supervisor: Dr R Hoppa
* McKinnon (2005-2009) Dept of Medical Microbiology Supervisor: Dr F Plummer
* Kroeker (2008 - 2014) Dept of Physiology & Immunology Supervisor: Dr A Halayko Supervisor: Dr K Coombs

**Teaching Awards:**

* Nominee Internal Medicine Educator Int Med 2006
* Nominee Teaching Excellence in Medicine Med II 2002
* Nominee Teaching Excellence in Medicine Med II 2001
* Honorable Mention Outstanding Clinician Teacher Med II 2000
* Honorable Mention Outstanding Clinician Teacher Med III 1998

***Professional Service Activities:***

# Society Memberships

* Canadian Academy of Health Sciences
* Canadian Society of Clinical Investigation
* Transplantation Society
* International Society of Nephrology
* American Society of Transplantation
* American Society of Histocompatibility and Immunogenetics
* American Society of Nephrology
* Canadian Society of Transplantation
* Royal College of Physicians and Surgeons of Canada
* Canadian Medical Association/Doctors Manitoba

# Board/Committee Memberships

#### University of Manitoba

* Senator, Faculty of Medicine, University of Manitoba (2005 to 2010)
* Chair, Mindel and Tom Olenick Research Award in Immunology (1998 to 2007)

#### Thorlakson Foundation Fund, University of Manitoba (2000 to 2002)

* Faculty of Medicine Research Committee (1999 to 2001)
* Senate Committee on Ethics in Research Involving Human Subjects (1999 to 2001)
* Core Internal Medicine Education Committee (1998 to 2001)

#### Faculty of Medicine Human Ethics Committee (1996 to 1999)

#### Provincial

#### Research Manitoba, Board Member (2011 to 2018)

#### Doctors of Manitoba, Board Member (2009 to 2010)

#### Chair, Kidney Foundation of Canada, Manitoba Branch, Research Committee (2001 to 2003)

* Manitoba Health Research Foundation Personnel Award Committee (1999 to 2001)

#### National

* Association of Medical Faculties of Canada (**AFMC**): Chair, Vice Dean Research Committee (**2019-present**)
* Kidney Foundation of Canada (**KFoC**): Research Council, Co-Chair (**2019-present**)
* CIHR Institute of Circulatory and Respiratory Health (**ICRH**), Institute Advisory Board (2013 to 2016)
* Research Canada (**RC**), Board Member (2012 to 2016)
* Canadian Society for Clinical Investigation (**CSCI**), Board Member (2010 to 2016)
* Kidney Foundation of Canada (**KFoC**): Biomedical Committee, Scientific Officer (2008 to 2013)
* Canadian Council for Donation and Transplantation (**CCDT**), Council Member (2005 to 2008)
* Canadian Society of Transplantation (**CST**), Councilor-at-Large (2002 to 2004)
* Canadian Institutes of Health Research (**CIHR**): Immunology and Transplantation Panel (2001 to 2004)
* Kidney Foundation of Canada (**KFoC**): Biomedical Committee, Member (1997 to 2000)

International

* USA, United Network for Organ Sharing (**UNOS**), Executive Board Member (2005 to 2007)
* Am. Soc. of Histocompatibility and Immunogenetics (**ASHI**), Past President (2007)
* Am. Soc. of Histocompatibility and Immunogenetics (**ASHI**), **Society President** (2005 and 2006)
* Am. Soc. of Histocompatibility and Immunogenetics (**ASHI**), Board Member (2003 to 2007)
* Am. Soc. of Histocompatibility and Immunogenetics (**ASHI**), Chair, Clinical & Scientific Affairs (2001 to 2003)
* Am. Soc. of Transplantation (**AST**): Education Committee (2004 to 2005)
* Am. Soc. of Transplantation (**AST**): Basic Science Review Committee (1997 to 2003)
* Am. Soc. of Transplantation (**AST**): Awards Committee (1999 to 2003)
* Am. Soc. of Nephrology (**ASN**): Basic Science Abstract Review Committee (2001 to 2003)

**Chair and Organizer of Scientific Conferences:**

* Annual Meeting, Canadian Society of Transplantation, Feb 2004, Mont-Tremblant, Quebec
* Assessment and Management of Immunologic Risk in Transplantation- a Canadian Council for Donation and Transplantation (CCDT) Consensus Forum, Jan 2005, Montreal, Quebec
* Highly Sensitized Patient and Living Donor Paired Exchange Registries – a Canadian Council for Donation and Transplantation (CCDT) Task Force, Oct 2005, Toronto, Ontario
* Annual Meeting, American Society of Histocompatibility and Immunogenetics, Oct 2007, Minneapolis, MN

##### Journal Editorial Board

* Member, Journal of the American Society of Nephrology Editorial Board (2005 to 2017)

##### Associate Editor, American Journal of Transplantation (2005-2007)

* Member, Kidney International Editorial Board (2005-2007)

##### Journal Reviewer

* Am Journal of Transplantation
* Clinical Journal of American Society of Nephrology
* Journal of American Society of Nephrology
* Journal of Immunology
* Kidney International
* Nephrology, Dialysis and Transplantation
* Tissue Antigens
* Transplantation

***Visiting Professor:***

1. **Combined Renal Research & Kidney Pancreas Transplant Conference, Vanderbilt University Medical Center**, Nashville, Tennessee (2021)
   * 1. “HLA Molecular Mismatch: A Tool For Precision in Transplant Medicine”
2. **Larry Chan Lectureship Visiting Professor, University of Colorado**, Aurora, Colorado (2021)
   * 1. “Alloimmune Risk Assessment: Advancing Precision Medicine in Kidney Transplantation”
3. **Renal Grand Rounds, Columbia University,** New York, New York (2020)
   * 1. “HLA Molecular Mismatch: Advancing Precision Medicine in Kidney Transplantation”

1. **Mount Sinai Hospital, RMTI Kidney, Special Presentation**, New York, New York (2020)
   * 1. “HLA Molecular Mismatch-Advancing Precision Medicine in Kidney Transplantation”
2. **UCLA Pathology Residents Conference**, Los Angeles, California (2020)
   * 1. “TCMR – 1990 to 2020 – an unmet need despite Calcineurin Inhibitors”
3. **UCLA Visiting Professorship Series**, Los Angeles, California (2020)
   * 1. “HLA Molecular Mismatch: A Tool for Precision Medicine”
4. **Transplant Conference**, **University of Minnesota,** Minneapolis, Minnesota (2020)
   * 1. “HLA Molecular Mismatch: A Tool for Precision Medicine”
5. **Renal Grand Rounds, Northwestern University**, Chicago, Illinois (2020)
   * 1. “Optimization of CNI to Improve Outcomes and Minimize Toxicity”
     2. “Transitioning to Precision Medicine in Kidney Transplantation”
6. **2020 Centre For Transplant Immunology Seminar Series, Cincinnati Children’s Hospital Research Foundation**, Cincinnati, Ohio (2020)
   * 1. “Transitioning from Empiric to Personalized Medicine in Kidney Transplantation”
7. **Medical University of Vienna**, Vienna, Austria (2019)
   * 1. “Tacrolimus Optimization in Transplant”
     2. “Innovative Risk Stratification in Kidney Transplantation”
8. **Duke University**, Durham, North Carolina (2019)
   * 1. “Transitioning from Empiric to Precision Medicine”
9. **Westmead – The University of Sydney**, Sydney, Australia (2019)
   * 1. “Evolution of HLA crossmatch from real to virtual”
     2. “HLA molecular mismatch – on the road to precision medicine in kidney transplantation”

1. **Thomas E. Starzl Transplantation Institute**, **University of Pittsburgh Medical Centre**, Pittsburgh, Pennsylvania (2019)
   * 1. “Transitioning from Empiric to Precision Medicine in Renal Transplantation”
2. **University of Wisconsin** **School of Medicine and Public Health**, Madison, Wisconsin (2018)
   * 1. “Transitioning from Empiric to Precision Medicine in Kidney Transplantation”
     2. “The Natural History, Prevention and Treatment of de novo DSA/ABMR”
3. **Leiden University Medical Center**, Leiden, The Netherlands (2018)
   * 1. “Natural History of de novo DSA/ABMR and Novel Strategies to Prevent and Treat ABMR”
4. **University Hospital Network, University of Toronto, MOT Rounds**, Toronto, ON (2018)
   * 1. “Time to Transition from Empiric to Precision Medicine in Kidney Transplantation”
5. **Royal Infirmary of Edinburgh**, Edinburgh, Scotland (2018)
   * 1. “HLA Epitope Matching- Transitioning from Empiric to Precision Medicine”
6. **The Ohio State University**, Charles G. Orosz Memorial Lecture, Columbus, Ohio (2017)
   * 1. “Improving Long-Term Graft Outcomes: Transitioning from Empiric to Precision Medicine”
7. **University of Alberta Hospital**, Edmonton, Alberta (2016)
   * 1. “High Performance in Organ Donation and Transplantation: Lessons Learned in Canada”
8. **University of Sydney**, Royal Prince Alfred Hospital, Sydney, Australia (2016)
   * 1. “HLA Diagnostics and the Sensitized Patient”
9. **Cambridge University**, Addenbrookes Hospital, Cambridge, UK (2016)
   * 1. “De novo DSA and ABMR: prevalence, risk factors and natural history”
10. **Case Western Reserve University**, Cleveland, OH USA (2016)
    * 1. “HLA Diagnostics and ABMR Management”
      2. “Strategies to Improve Long-Term Graft Outcomes: Can We Do Better With What We Have?”
11. **University of Alabama at Birmingham Comprehensive Transplant Institute**, Birmingham, AB USA (2016)
    * 1. “Strategies to Improve Long-Term Graft Outcomes: Begin at the Beginning”
12. **Albert Einstein College of Medicine & Montefiore Medical Center**, New York, NY USA (2016)
    * 1. “Strategies to Improve Long-Term Graft Outcomes: Can We Do Better With What We Have”
13. **The Mount Sinai Medical Center,** New York, NY USA (2015)
    * 1. “De Novo DSA in Kidney Transplants – Begin at the beginning to prevent the end”
14. **University of Pittsburgh, Thomas E. Starzl Transplantation Institute,** Pittsburgh, PA USA (2014)
    * 1. “De Novo DSA Risk Factors and Impact on Kidney Allograft Survival”
15. **University of Basel**, Basel, Switzerland (2012)
16. “Mechanisms of Graft Loss”
17. **Emory University,** Atlanta, Georgia, USA (2010)
    * 1. “Post Transplant Monitoring for HLA Antibodies”
18. **University of Alberta, University of Calgary and University of British Columbia** (2009)
    * 1. “De Novo Antibody Post Transplant and an Update of the Paired Exchange Program”
19. **McGill University Health Centre,** Montreal, Quebec, Canada (2009)
    * 1. “Current Challenges for Organ Transplantation in Canada”
20. **University Health Network & Mount Sinai Hospital,** Toronto, Ontario, Canada (2009)
    * 1. “Impact of HLA Antibodies Pre and Post Transplant”
21. **Clinical Transplant Conference, Northwestern University,** Chicago, Illinois, USA (2008)
    * 1. “Developing Urine Biomarkers in Renal Transplantation”
22. **University of Utah,** Salt Lake City USA (2008)
    * 1. “Developing Biomarkers in Transplantation”
23. **University of Pittsburgh, Thomas E. Starzl Transplantation Institute,** Pittsburgh, PA USA (2007)
    * 1. “Developing Biomarkers of Renal Injury Using Proteomics”
24. **University of Perth,** Perth, Australia(2006)
    * 1. “Research: Defining Biomarkers in Transplantation”
      2. “Clinical: Solutions for the Sensitized Patient”
25. **McGill University Health Centre,** Montreal, QC Canada (2006)
    * 1. “Research: Defining Biomarkers in Transplantation”
      2. “Clinical: Solutions for the Sensitized Patient”
26. **University of Calgary, Rachel McKenna Memorial Lectureship,** Calgary, Alberta, Canada (2005)
    * 1. “Solutions for the Sensitized Patient”
27. **University of Alberta,** Edmonton, Alberta, Canada (2004)
    * 1. “Significance of Detecting Pre-transplant Immunologic Memory”
28. **Lerner Research Institute and Cleveland Clinic,** Cleveland, Ohio, USA (2003)
    * 1. “The Role of the Transplant Laboratory in Pre and Post Transplant Monitoring of the Renal Allograft”
29. **University of Calgary,** Calgary, Alberta, Canada (2003)
    * 1. “Non-invasive Diagnosis of Rejection”
30. **University of Calgary,** Calgary, Alberta, Canada (2003)
    * 1. "Detection of Immunologic Memory Pre-Transplant"
31. **Emory University,** Atlanta, GA, USA (2003)
    * 1. "Urine Spectroscopy"
32. **University of Toronto,** Toronto, ONT, Canada (2002)
    * 1. “Novel non-invasive strategies to diagnose renal allograft rejection”
      2. “Role of Flow cross-match in pre-transplant work-up”
33. **Yale University,** New Haven, CT, USA (2002)
    * 1. “Non-invasive monitoring of the allograft: What does sensitivity and specificity have to do with it”
      2. “Advances in Pre-Transplant Cross Matching: When does negative mean negative and positive mean positive?”
34. **Dalhousie University,** Halifax, NS, Canada (2001)
    * 1. "Mechanisms of Rejection and Novel Methods of Non-invasive Detection."
35. **University of Innsbruck,** Innsbruck, Austria (2001)
    * 1. “Mechanisms of Allograft Rejection and Strategies for Monitoring Rejection”
36. **University of Western Ontario,** London, Ontario, Canada (2000)

### “Early detection of allograft inflammation”

* + 1. “Immunologic Memory is it still an issue in Transplantation”

1. **University of Basel,** Basel,Switzerland (2000)
   * 1. “Early Detection of Allograft Inflammation”
     2. “Impact of anti-HLA antibodies Pre-transplant”
2. **University of Cincinnati**, Cincinnati, OH, USA (2000)
   * 1. “Early Detection of Allograft Inflammation”
     2. “The Importance of Immunogenetics in Solid Organ Transplantation”
     3. “New Developments in Solid Organ Cross-Matching”
3. **University of Rochester, Rochester**, NY, USA (1999)
   * 1. “Predicting Rejection: Is Early Diagnosis Achievable and Important?”

***Invited Speaker:***

1. **American Society for Histocompatibility and Immunogenetics (ASHI) 47th Annual Meeting - Virtual** (2021)
   * 1. “The Wonderful World of non-invasive transcriptomic signatures”
2. **Sensitization in Transplantation: Assessment of Risk (STAR) Working Group Webinar: 2022 Reports and Planning – Virtual** (2021)
   * 1. “Primary (Naïve or De Novo) Allo-Immune Response”
3. **American Transplant Congress 2021 Virtual Connect** (2021)
   * 1. “Live Video Controversy Discussion: Should We HLA Match in Organ Allocation – Yes”
     2. “Pro: Why Wait: We Should be Doing Epitope Matching Now”
4. **34th European Immunogenetics and Histocompatibility Conference – Virtual** (2021)
   * 1. “HLA Molecular Mismatch – A prognostic and predictive biomarker for primary alloimmunity”
5. **Astellas China – Kidney Transplantation Society of China International Exchange and Promotion Association for Medical and Healthcare Annual Meeting – Virtual** (2021)
   * 1. “HLA Molecular Mismatch – on the Path to Precision Medicine in Transplantation”
6. **Cutting Edge of Transplantation (CEOT)-Transplant Summit 2021 – Virtual** (2021)
   * 1. “Immune Monitoring – Intro: Can you handle the truth?”
     2. “End Points: Kidney – Industry – Designing clinical trials with next gen endpoints”
     3. “The Future – Goldilocks diagnostics: too much, too little, just right”
     4. “Impact of CAMR on the long-term outcomes of transplanted kidneys”
7. **6th National Virtual Congress of The Spanish Society of Transplantation-SET 2021 – Virtual** (2021)
   * 1. “Before Transplantation: HLA matching, epitope matching and other options. The right way to go?”
     2. “Humoral response against HLA antigens: state of the art”
8. **Astellas Webinar – MST Transplant Webinar Series – Malaysia - Virtual** (2021)
   * 1. “Strategies to optimize CNI based treatment and improve long-term clinical outcomes in solid organ transplantation”
9. **Astellas Webinar (Indonesia-Philippines-India) – Virtual** (2020)
   * 1. “Alloimmune Risk Assessment: Advancing Precision Medicine in Kidney Transplantation”

1. **ASHI 2020 Virtual Annual Meeting, Rose Payne Award Presentation** (2020)
   * 1. “Molecular Mismatch: The renaissance of HLA in kidney transplantation”
2. **NIAID Council Meeting**, Bethesda, MD (2020)
   * 1. “HLA Molecular Mismatching: A Prognostic/Predictive Biomarker for Clinical Trial Design in Solid Organ Transplantation”
3. **Astellas Sponsored, EMKT**, Seoul, South Korea (2020)
   * 1. “Optimizing Tacrolimus: To Prevent DSA Formation and Improve Outcomes”
     2. Video recording – “How to Keep Your Audience Engaged and Managing the Challenging Questions in Transplantation”
4. **Astellas Sponsored, with Thai Transplantation Society**, Bangkok, Thailand (2020)
   * 1. “Optimizing Tacrolimus to Prevent DSA Formation and Improve Outcomes”
5. **American Association of Blood Banks (AABB) 2019 Annual Meeting**, San Antonio, Texas (2019)
   * 1. “HLA Class II Molecular Mismatch – A Prognostic/Predictive Biomarker in Kidney Transplantation”
6. **Astellas Sponsored, 16th Congress of the Asian Society of Transplantation (CAST)**, New Delhi, India (2019)
   * 1. “Optimizing Tacrolimus to Prevent DSA Formation and Improve Outcomes”
7. **45th Annual American Society for Histocompatibility and Immunogenetics (ASHI)/Banff Joint Scientific Meeting**, Pittsburgh, Pennsylvania (2019)
   * 1. “Individualizing Post-Transplant Immune Monitoring and Consequences for Response to Therapy”
     2. “ASHI/Banff Joint Scientific Meeting Summary”
8. **Transplant Immunosuppression 2019: Hot Topics**, Minneapolis, Minnesota (2019)
   * 1. “CNI Minimization”
     2. “Epitope Matching”
9. **4th International Workshop on Clinical Tolerance**, Pittsburgh, Pennsylvania (2019)
   * 1. “Better Patient Selection through better Typing & Matching”
10. **Paul I. Terasaki Antibody Symposium**, Los Angeles, California (2019)
    * 1. “HLA Molecular Mismatch Score – a Prognostic/Predictive Biomarker”
11. **American Transplant Congress 2019 (ATC)**, Boston, Massachusetts (2019)
    * 1. “Debate – PRO: Monitoring for Donor Specific Antibody on a Routine Basis IS Necessary!”
      2. “Impact of HLA Epitope Matching on T-Cell Mediated Rejection”
      3. “HLA Molecular Mismatch and DSA Assessment”
      4. “Who Should be Treated for AMR?”
12. **10th Congress of the International Pediatric Transplant Association (IPTA**), Vancouver, British Columbia (2019)
    * 1. “Balancing Utility and Equity in the Organ Allocation System”
      2. “Epitope Matching for Organ Allocation – Future Matching Strategies”
13. **CSN Annual General Meeting 2019**, Montreal, Quebec (2019)
    * 1. KFOC Medal of Research Excellence Presentation: “A career in pursuit of precision medicine in transplantation”
14. A**stellas Sponsored Talk, Kidney Transplant Workshop**, Taipei, Taiwan (2019)
    * 1. ‘Transitioning from Empiric to Precision Medicine in Kidney Transplantation”
15. **Taiwan Transplant Surgical Society Annual Spring Meeting**, Taipei, Taiwan (2019)
    * 1. “What Matters to Improve Long Term Survival – A Real World Evidence”
16. **The Transplantation Society (TTS) Consensus Guidelines for Diagnosis and Treatment of Antibody Mediated Rejection (ABMR),** Los Angeles, California (2019)
    * 1. “Clinical Course of Chronic ABMR”
17. **Cutting Edge of Transplantation 2019 (CEoT)**, Phoenix, Arizona (2019)
    * 1. “HLA Molecular Mismatch Assessment”
18. **Astellas Sponsored Lecture, EMKT 2019**, Busan, South Korea (2019)
    * 1. “Optimization of tacrolimus therapy to minimize primary alloimmunity (TCMR, DSA and ABMR)”
      2. “Epitope mismatch and DSA development”
19. **Astellas Sponsored Lecture, EMW-TRUST Web Symposium**, Busan, South Korea (2019)
    * 1. “Precision Medicine in Transplantation”
20. **Astellas Sponsored Lecture, Changhai Hospital**, Shanghai, China (2019)
    * 1. “Optimizing Immunosuppression, Epitope Mismatch and DSA development”
21. **Astellas Sponsored Lecture, First Affiliated Hospital of Zhejiang University**, Hangzhou, China (2019)
    * 1. “Optimizing Immunosuppression and HLA DR/DQ Molecular Mismatch and non-invasive monitoring to Prevent DSA Formation”
22. **Clinical Review Symposium, Netherlands Transplant Society**, Utrecht, The Netherlands (2018)
    * 1. “Transitioning from Empiric to Precision Medicine”
23. **10th Symposium – Immunopathology in Renal Transplantation**, Buenos Aires, Argentina (2018)
    * 1. “Clinical Significance of HLA Antibodies”
      2. “Treatment of Humoral Rejection”
      3. “In Clinical Research”
24. **Indian Society of Organ Transplantation** **(ISOT),** Hyderabad, India (2018)
    * 1. “State of the art for diagnosis of antibody mediated rejection”
25. **FDA Workshop: Evidence-Based Treatment Decisions In Transplantation**, Silver Spring, Maryland (2018)
    * 1. “HLA Molecular Mismatch – A Prognostic Biomarker for Primary Alloimmunity”
26. **Astellas Sponsored Lecture, McMaster University and Western University Transplant Programs,** Woodstock, Ontario (2018)
    * 1. “Time to Transition from Empiric to Precision Medicine in Kidney Transplantation”
27. **One Lambda Inc., - 2018 Chinese Transplant Congress**, Chengdu, China (2018)
    * 1. “Time to Transition from Empiric to Precision Medicine in Kidney Transplantation”
28. **The Transplantation Society (TTS 2018) 27th International Congress of the Transplantation Society Meeting**, Madrid, Spain (2018)
    * 1. “Histocompatibility Testing (Pre & Post)”
29. **One Lambda Inc., 2018 European Clinical Histocompatibility Workshop**, Prague, Czech Republic (2018)
    * 1. “Epitope Matching: Transitioning from Empiric to Precision Medicine”
30. **American Transplant Congress (ATC) 2018 Annual Meeting**, Seattle, Washington (2018)
    * 1. “Is There Anything in the Pipeline for ABMR?”
31. **9th Annual CTOT/CTOT-C Mechanistic Studies in Transplantation Workshop**, Bethesda, Maryland (2018)
    * 1. “Transitioning from Empiric to Precision Medicine – Epitope Matching”
32. **One Lambda Inc., 32nd Advanced HLA Technical Workshop**, Palm Springs, California (2018)
    * 1. “Epitope Matching vs. HLA Matching in Organ Transplantation”
33. **Astellas Symposium**, Sydney, Australia (2018)
    * 1. “Tacrolimus Optimization and the modulation required with epitope mismatch” & “Non-invasive biomarkers of rejection including CXCL10/CCL2 in urine”
34. **Astellas Transplant Forum 2018**, Bangkok, Thailand (2018)
    * 1. “Strategies to Improve Long-Term Graft Outcomes: Can We Do Better With What We Have?”
35. **Astellas Standalone Symposium**, Hanoi, Vietnam (2018)
    * 1. “De Novo DSA and ABMR”
36. **Astellas Symposium with Society of Transplantation, Singapore**, Singapore, (2018)
    * 1. “Optimizing CNI in relation to dnDSA (de novo donor-specific antibody) – the state of art for long term graft survival”
37. **XV Brazilian Society for Organ Transplantation Congress**, Foz do Iguaçu (Iguassu Falls), Brazil (2017)
    * 1. “A Novel Approach Enabling Personalized Immunosuppression?”
      2. “Strategies to Improve Long-Term Graft Outcomes in Kidney Transplantation”
38. **Transplant Immunosuppression 2017 Course**, Minneapolis, Minnesota (2017)
    * 1. “Development of new onset DSA – risk factors & natural history”
      2. “Development of new onset DSA – How I Do It”
      3. “Epitope Matching To Improve Outcomes”
      4. “Precision Medicine & Individualization of Immunosuppression”
39. **European Society for Organ Transplantation (ESOT) 2017 Congress**, Barcelona, Spain (2017)
    * 1. “DSAs as surrogate endpoint for drug development”
40. **American Society for Histocompatibility and Immunogenetics (ASHI) 43rd Annual Meeting**, San Francisco, California (2017)
    * 1. “HLA Molecular Mismatch Assessment – a tool for quantifying patient risk” (One Lambda Symposium)
      2. “HLA Beyond the Whole Molecule to Personalize Patient Care”
41. **VI Chilean Society of Transplant Congress**, Santiago, Chile (2017)
    * 1. “Biomarkers and Their Use In Graft Rejection”
      2. “Current Status of Alloantibodies In the Pathology and Evolution of Kidney Transplant”
      3. “Focus On Causal Pathways Leading To Kidney Allograft Loss and Optimizing Baseline Immunosuppression To Prevent It”
      4. “Focus On HLA Matching – Where We Are Today and Where We Need To Go In the Future”
42. **8th Annual CTOT/CTOT-C Mechanistic Studies in Transplantation Workshop**, Bethesda, Maryland
    * 1. Aptamers: A Multiplex Quantitative Proteomic Discovery Platform
43. **American Transplant Congress (ATC) 2017 Annual Meeting**, Chicago, Illinois (2017)
    * 1. “B Cell/Antibody Mediated Rejection” – *Pre-Course Lecture*
      2. “Basic- How B Cells Influence the Immune Response” – *Meeting Symposia*
44. **National Kidney Foundation (NKF) 2017 Spring Clinical Meetings (SCM17)**, Orlando, Florida, (2017)
    * 1. “Recognizing and Managing Acute Rejection”
      2. “Treatment of Antibody-Mediated Rejection”
45. **FDA Workshop: Antibody Mediated Rejection in Kidney Transplantation**, Washington, DC (2017)
    * 1. “A New Paradigm: HLA Epitope Based Donor/Recipient Mismatch Assessment”
      2. “Impact of Acute and Chronic AMR on Graft and Patient Survival”
46. **BANFF-SCT 2017 Joint Scientific Meeting**, Barcelona, Spain (2017)
    * 1. “The Path Towards Next Generation Sequencing Application to Solid Organ Transplants”
      2. “DSA Positive and Then – To Biopsy or Not?”
47. **Advancing Transplantation: Collaborate, Innovate, Act, Astellas Symposium**, Stockholm, Sweden (2017)
    * 1. “Adherence and HLA Antibody Formation in Transplantation”
48. **Asia Pacific Transplant Caucus 2017, Astellas Symposium**, Jeju, Korea (2017)
    * 1. “Early Recognition of Subclinical Rejection”
49. **Hong Kong Hospital Authority Renal Commissioned Training Program 2017**, Hong Kong, China (2017)
    * 1. “Non-invasive Monitoring of Renal Graft”
      2. “Barriers to Long-Term Survival of Renal Graft”
      3. “Antibody-Mediated Rejection Management”
50. **Astellas Symposia**, Hong Kong, China (2017)
    * 1. “Understand the Common Causes of Graft Loss and Improvement Measures”
51. **Astellas Symposia**, Jakarta, Indonesia (2017)
    * 1. “Current Status of Alloantibody Measurement in Transplantation and Biomarkers for Kidney Allograft Survival”
52. **Astellas Symposia**, Taiwan, China (2017)
    * 1. “Optimizing Immunosuppression to Improve Kidney Transplant Outcomes”
53. **Clinical Transplantation Update Day**, Parma, Italy (2016)
    * 1. “How To Prevent Long Term Graft Failure? Best Matching Strategies: Kidney”
54. **2016 CST-CNTRP-SQT Joint Scientific Meeting**, Quebec City, Quebec (2016)
    * 1. “The Utility of Routine Post-transplant Monitoring For de novo DSA”
      2. “Personalized Approach to Transplantation and Immunosuppressive Therapy”
55. **American Society of Transplantation, Timely Topics in Transplantation (T3) Webinar Series** (2016)
    * 1. “An Update on Current Concepts in Donor Specific Antibody Testing”
56. **American Society for Histocompatibility and Immunogenetics (ASHI)**, St. Louis, Missouri (2016)
    * 1. Terasaki Award Lecture “HLA Matching to Improve Outcomes”
57. **FDA Meeting on Patient Focused Drug Development**, Silver Spring, Maryland (2016)
    * 1. “Long-term Graft Outcomes, Etiology, Risk Factors and Natural History
58. **One Lambda Evening Symposium on Donor Specific Antibody Monitoring**, Hong Kong, China (2016)
    * 1. “Strategies to Improve Long-Term Graft Outcomes: Begin at the Beginning”
59. **26th International Congress of the Transplantation Society (TTS)**, Hong Kong, China (2016)
    * 1. “Biomarkers for Renal Allograft Survival”
      2. “Current Status of Alloantibody Measurement and Management in Transplantation”
60. **2016 Annual Meeting of the American Transplant Congress-Thermo-Fisher Luncheon Symposium**, Boston, Massachusetts (2016)
    * 1. “Strategies to Improve Long-Term Graft Outcomes: Begin at the Beginning”
61. **Novartis Transplant Forum**, Melbourne, Australia (2016)
    * 1. “De novo DSA and ABMR: prevalence, risk factors and natural history”
62. **Astellas Satellite Symposium to Transplantation Science Symposium (TSS) Asian Regional Meeting 2016**, Tokyo, Japan (2016)
    * 1. “De Novo Donor-Specific Antibody: Why is it Important For the Long-Term Outcomes and What Are the Risks?”
63. **One Lambda, 30th Advanced HLA Technical Workshop**, Palm Springs, California (2016)
    * 1. “Strategies to Improve Long-Term Graft Outcomes: Begin at the Beginning”
64. **Cutting Edge of Transplantation 2016** **(CEOT)**, Phoenix, Arizona (2016)
    * 1. “Long-term Graft Survival – It’s All About Anti-Donor Antibodies”
65. **Transforming Transplantation – The Expert Summit 2015**, Vienna, Austria (2015)
    * 1. “Antibody-mediated rejection: practical considerations in diagnosis and treatment”

1. **Transplant Immunosuppression 2015**, Minneapolis, Minnesota (2015)
   * 1. “Antibody: a brief history and the impact of DSA”
     2. “Are all DSA equal?”
     3. “Improving outcome and decreasing sensitization by epitope matching”
     4. “Approach to de novo DSA: bx? Treat?”
2. **2015 Banff-CST Joint Scientific Meeting**, Vancouver, BC (2015)
   * 1. “The Future of HLA: Eplet Mismatch to Improve Transplant Candidates Risk Assessment”
3. **The Transplantation Society – Consensus Conference on IS Trials**, Washington DC (2015)
   * 1. “How predictive is de novo DSA as a biomarker measure of a surrogate endpoint for long-term graft loss?”
4. **FDA Workshop – Surrogate Endpoints in Clinical Trials of Kidney Transplantation**, Washington DC (2015)
   * 1. “Unmet Medical Need Topic #3: Patients with De Novo Donor Specific Antibodies”
     2. “Donor Specific HLA Antibodies and the Highly Sensitized Patient – Various Aspects, Different Perspectives”
5. **Astellas Satellite Symposium to ESOT Congress 2015: Care of the Kidney Patient with HLA Antibodies**, Brussels, Belgium (2015)
   * 1. “Minimising de novo Antibodies”
6. **Improving Long-Term Outcomes in Transplant Immunosuppression**, Panama City, Panama (2015)
   * 1. “Begin at the Beginning to Prevent the End”
7. **2015 European Clinical Histocompatibility Workshop**, Budapest, Hungary (2015)
   * 1. “High Resolution Typing in Solid Organ Transplantation: Ready for Prime Time?”
8. **Hong Kong Societies of Nephrology & Transplantation**, Hong Kong, China (2015)
   * 1. “De novo DSA and ABMR – Begin at the Beginning to Prevent the End”
9. **Astellas Advagraf Symposium**, Ho Chi Minh, Vietnam (2015)
   * 1. “De novo DSA and ABMR – Begin at the Beginning to Prevent the End”
10. **18th Annual Scientific Meeting of the Malaysian Society of Transplantation**, Kuala Lumpur, Malaysia (2015)
    * 1. “Improving long-term outcomes in kidney transplantation: Begin at the Beginning”
11. **American Transplant Congress** **2015**, Philadelphia, Pennsylvania (2015)
    * 1. “The High-Risk Patient: Does Monitoring AMR Improve Outcomes?”
      2. “Assessing Immunological Risk Post Transplantation by Quantifying Epitope Mismatches”
12. **One Lambda, Inc., 28th Clinical Histocompatibility Workshop**, Henderson, Nevada (2015)
    * 1. “NGS In Solid Organ Transplant – Ready for Primetime?”
13. **15th Annual Canadian Transplant Forum**, Toronto, Ontario (2014)
    * 1. “Donor Evaluation: Immunological Aspects – Case 3”
14. **American Society of Nephrology, Kidney Week 2014**, Philadelphia, Pennsylvania (2014)
    * 1. “What It All Means for the Graft”
15. **2014 Annual Meeting of the Transplantation Society of Taiwan**, Taipei, Taiwan (2014)
    * 1. “Prevention Strategy DSA in Kidney Transplantation”
      2. “Dose Strategy of Tacrolimus Regimen Post Kidney Transplantation”
16. **Korean Transplant Society**, Seoul, South Korea (2014)
    * 1. “DSA and Long Term Graft Outcomes in Kidney Transplant Recipients”
17. **Chinese Research Hospital Association of Transplantation Founding Meeting & 2014 China Organ Transplantation Xiangshan Forum**, Beijing, China (2014)
    * 1. “DSA Impact on Long-Term Kidney Transplant Outcomes: Clinical Strategies to Prevent DSA Formation”
18. **World Transplant Congress**, San Francisco, California (2014)
    * 1. “Epitope Mismatch Predicts De Novo DSA After CNI Withdrawal in Low-Risk Kidney Transplant Recipients”
19. **ASHI-AMLI Symposium, FOCIS 2014 Meeting**, Chicago, Illinois (2014)

i. Personalized Treatment for Autoimmune Diseases and Transplantation: Laboratory Analysis of Molecular Pathways, Targeted Therapies, and Genomic Characterization

1. **Necker “Jean Hamburger” Seminars in Nephrology**, Institute Pasteur, Paris, France (2014)
   * 1. “De Novo Donor-specific HLA Antibody Post Kidney Transplant”
2. **2014 Annular Congress**, Taipei, Taiwan (2014)
   * 1. “Advance Organ Transplant Workshop”
     2. “DSA and Graft Survival in Kidney Transplantation”
3. **Canadian Society of Transplantation (CST) 2014 Annual Scientific Meeting**, Montreal, Quebec
   * 1. “Transplanting the Highly Sensitized Recipient”
4. **AST Cutting Edge of Transplantation (CEOT)**, Phoenix, Arizona (2014)
   * 1. “Chronic Antibody-Mediated Rejection: Too Little or Too Much Immunosuppression”
5. **12th Congress of the International Society for Organ Donation and Procurement (ISODP)**, Sydney, Australia (2013)
   * 1. “Lessons from the Canadian Living Donor Paired Exchange”
6. **American Society for Histocompatibility & Immunogenetics (ASHI)**, Chicago, Illinois (2013)
   * 1. “De Novo Donor Specific Antibody Post-Transplant”
7. **Astellas Symposium at ESOT Congress**, Vienna, Austria (2013)
   * 1. “Clinical Implications of DSA”
8. **49th Annual Meeting of Japanese Society for Transplantation 2013**, Kyoto, Japan (2013)
   * 1. “The Natural Course of Antibody Mediated Allograft Injury”
9. **American Transplant Congress (ATC)**, Seattle, Washington (2013)
   * 1. “DSA and Transplant Outcomes”
10. **Canadian Society of Transplantation (CST) 2013 Annual Scientific Meeting**, Lake Louise, AB (2013)
    * 1. “Case 2: AMR – The Known Unknown”
      2. “Post Tx DSA: To Screen or Not to Screen”
11. **27th Advanced HLA Technical Workshop**, Orlando, FL, (2013)

i. “Improving Patient Outcomes: Post-Transplant DSA Monitoring and Early Intervention”

1. **American Society of Transplantation Cutting Edge of Transplantation**, Phoenix, AZ (2013)

i. “The Natural Course of Antibody-mediated Allograft Injury”

1. **13th Annual Canadian Transplant Forum**, Toronto, ON, Canada (2012)

i. “Acceptable Mismatch in Kidney Transplantation for the Sensitized Patient”

1. **American Society for Histocompatibility and Immunogenetics (ASHI)**, San Juan, Puerto Rico, USA (2012)
   * 1. “Clinical Biomarkers”
2. **Société Québécoise de Transplantation,** Pierre Daloze Lecturer, Quebec City, QC, Canada (2012)
   * 1. “What can we do for the sensitized patient?”
3. **Novartis Canada Satellite Symposium at Canadian Society of Transplantation (CST) 2012 Annual Scientific Meeting**, Québec City, QC (2012)

i. “When Data is not a Dirty Word: the Future of Information Management in Canadian Transplant Centres”

1. **International Pediatric Transplant Congress**, Montreal, QC, Canada (2011)
   * 1. “Genomic and proteomic approaches in transplantation”
2. **Swiss Transplant Society,** Interlaken, Switzerland (2011)
   * 1. “Impact of donor specific antibodies in transplantation”
3. **XXIII International Congress of the Transplantation Society**, Vancouver, BC, Canada (2010)
   * 1. “The potential of proteomics and metabolomics in the management of solid organ transplant patients”
     2. “Evolution of tissue typing”
4. **US Food and Drug Administration (FDA) Antibody Mediated Rejection Workshop**,Wash DC, (2010)
   * 1. “De novo DSA post-transplant”
5. **European Immunogenetics and Histocompatibility Conference (EFI)**, Florence, Italy (2010)
   * 1. “Post-transplant monitoring”
6. **American Transplant Congress**, San Diego, California, USA (2010)
   * 1. “De Novo donor Specific Antibody (DSA) Is Associated with Decreased Kidney Graft Survival and Subclinical Antibody Mediated Rejection”
7. **New Frontiers in Immunology - International Symposium**, Winnipeg, Manitoba, Canada (2009)
   * 1. “Detecting Sub-clinical Rejection in Kidney Transplantation”
8. **Roche Nephrology & Transplant Symposium (RNTS)**, Melbourne Australia (2009)
   * 1. “Patient Screening, Donor Screening and Crossmatching”
9. **Canadian Society of Transfusion Medicine,** Ottawa, Ontario, Canada (2009)
   * 1. “Challenges in Kidney Transplantation: Finding solutions for the sensitized patient”
10. **American Society of Transplantation Winter Symposium,** Banff, Alberta, Canada (2009)
    * 1. “Sensitization: Diagnosis and Risk Stratification”
11. **American Society of Nephrology Renal Week 2008**, Philadelphia, Pennsylvania, USA (2008)
    * 1. “Novel Immunologic Assays to Assess the Risk for Antibody-Mediated Rejection”
12. **AST Fellows Symposium on Transplant Medicine**, Grapevine, Texas, USA (2008)
    * 1. “Immune Risk Assessment”
      2. “Indications for Solid Organ Transplantation: Organ Specific Biomarkers in Transplant Rejection”
13. **ISN Nexus Symposium on Transplantation,** Rome, Italy (2008)
    * 1. “Proteomics”
14. **XXII International Congress of The Transplant Society,** Sydney, Australia (2008)
    * 1. “Strategies for Transplanting Highly Sensitized Patients in Canada”
      2. “Detection and Implications of Anti-Donor Antibodies”
      3. “Proteomics Will Alter Clinical Practice”
15. **Provincial Renal Transplant Day,** Vancouver, British Columbia, Canada (2008)
    * 1. “Solutions for the Sensitized Patient”
16. **American Transplant Congress,** Toronto, Ontario, Canada (2008)
    * 1. “Anti-Donor Antibody Responses: Their Detection and Clinical Relevance”
17. **17th Annual Alberta Nephrology Days,** Jasper, Alberta, Canada (2008)
    * 1. “Challenges and Solutions to the Management of the Highly-Sensitized Transplant Recipient”
18. **12th American Society of Transplantation Annual Winter Symposium,** Palm Springs, California, USA (2008)
    * 1. “Paired Exchange or Acceptable Mismatch: Which Road to Take?”
19. **Transplant Histocompatibility Conference,** Chicago, Illinois, USA (2008)
    * 1. “HLA Tissue Typing, Crossmatching, Antibody Identification, Specificity
20. **A Satellite Symposium of the 9th Banff Conference on Allograft Pathology, ATAGC**, Edmonton, Alberta, Canada (2007)
    * 1. “Update of Metabolomic & Proteomic Studies in Kidney Transplants”
21. **American Society of Transplantation**, San Francisco, California, USA (2007)
    * 1. “Anti-Donor Antibody Responses: Clinical Relevance and Treatment”
22. **ASEATTA, Annual Meeting,** Thailand (2006)
    1. “Significance of Low-Titre HLA Antibodies”
23. **3rd International Summer School on Immunogenetics,** Bangkok, Thailand (2006)
    * 1. “Solid Organ Transplantation”
24. **The European Society for Clinical Cell Analysis (ESCCA),** Stresa, Italy (2006)
    * 1. “Diagnosis of Acute Antibody Mediated Graft Rejection”
25. **World Transplant Congress,** Boston, Massachusetts, USA (2006)
    * 1. “Anti-Donor Antibody Responses: Their Detection & Clinical Relevance
      2. “Proteomics & Metabolomics
26. **Joint CSMLS / MSMLT Congress,** Winnipeg, Manitoba, Canada (2006)
    * 1. “Proteomic Approach to Develop Non Invasive Diagnostics”
      2. “Impact of Donor Specific Antibodies and Allograft Outcome”
27. **Canadian Society of Transplantation Annual Scientific Meeting,** Mont-Tremblant, Quebec, Canada (2006)
    * 1. “Detection of Renal Tubular Injury in Cardiac Transplant Recipients by Urine Proteomic Analysis”
28. **Swiss Meeting for Assessment and Management of Immunological Risk in Transplantation,** Basel, CH (2005)
    * 1. “Detection of Donor-Specific Antibodies Pre-Transplant in Renal Allograft Recipients: Clinical Importance and Cost Effectiveness”
29. **31st Annual American Society of Histocompatibility and Immunogenetics,** Washington DC, USA (2005)
    * 1. “Summary of Clinical: What’s New, What’s Hot”
30. **38th Annual Congress of the German Society for Transfusion Medicine and Immunohaematology,** Erfurt, Thuringia, Germany (2005)
    * 1. “Relevance of Antibodies in Transplantation of Solid Organs – Mechanisms of Acute and Chronic Rejection”
31. **2nd International Summer School on Immunogenetics,** San Miguel De Allende, Guanjuato, Mexico (2005)
    * 1. “Factors Predictive of Acute Rejection in Organ Transplantation”
      2. “HLA Antibody and Donor Reactivity: Risk for Early Graft Rejection and Loss”
      3. “Future Challenges in Clinical Laboratory Support for Transplantation”
32. **IX Brazilian Congress of Organs Transplantation,** Salvador – Bahia, Brazil (2005)
    * 1. “Antibody Mediated Rejection: Diagnostic Problems”
      2. “The Role of the Histocompatibility Laboratory in the Post-Transplant Immunologic Monitoring”
      3. “Pre-Transplant Immunologic Risk Factors in Kidney Transplantation”
33. **3rd World Congress of Nephrology,** Singapore, Asia (2005)
    * 1. “What is the Role of Protocol Transplant Biopsies in Routine Clinical Practice?”
34. **American Society of Histocompatibility and Immunogenetics, Regional Education Workshop,** New Orleans, USA (2005)
    * 1. **“**Future Challenges in Clinical Laboratory Support for Transplantation”
35. **American Society of Histocompatibility and Immunogenetics, Regional Education Workshop,** Phoenix, Arizona, USA (2005)
    * 1. **“**Future Challenges in Clinical Laboratory Support for Transplantation”
36. **19th European Immunogenetics & Histocompatibility Conference,** Instanbul, Turkey (2005)
    * 1. “Significance of Low Titre Donor Specific HLA Antibodies Only Detected by Flow-Bases
      2. Techniques: The Manitoba Experience”
37. **AST/CST Joint Winter Symposium,** Banff, Alberta, Canada (2005)
    * 1. “HLA Antibody and Donor Reactivity: Risk for Graft Dysfunction”
38. **NIDDK Glomerular Disease Workshop,** Bethesda, Maryland, USA (2005)
    * 1. “Urine Protein Profiling with Mass Spectroscopy”
39. **ASTS 5th Annual State of the Art Winter Symposium,** Miami Beach, Florida, USA (2005)
    * 1. **“**Genomics, Proteomics and Metabonomics”
40. **Annual Transplant Atlantic Meeting,** Halifax, NS, Canada (2004)
    * 1. “Pre-Transplant Risk Assessment Can Improve Clinical Transplant Outcomes”
41. **30th Annual American Society of Histocompatibility and Immunogenetics,** San Antonio, Texas, USA (2004)
    * 1. “Future Challenges in Clinical Laboratory Support for Transplantation”
42. **Canadian Society of Medical Laboratory Science Conference,** Saskatoon, Saskatchewan, Canada (2004)
    * 1. “HLA Antibodies and their Clinical Significance”
      2. “New Methods to Detect Renal Allograft Rejection”
43. **5th Annual Joint Transplant Meeting of the American Society Transplant Surgeons and the American Society of Transplantation,** Boston Massachusetts, USA (2004)
    * 1. “Clinical Significance of HLA Antibodies”
      2. “Clinical Application and Risk Management”
44. **American Society of Histocompatibility and Immunogenetics, Midwestern Regional Education Workshop,** Columbus, Ohio, USA (2004)
    * 1. “Crossmatching for Solid Organ Transplantation”
45. **The International HLA & Transplantation Conference,** Los Angeles, California, USA (2004)
    * 1. “Pre-formed Antibodies in Transplantation”
46. **29th American Society of Histocompatibility and Immunogenetics,** Miami Beach, Florida, USA (2003)
    * 1. “Pretransplant Detection of HLA Ab: Contraindication vs. Risk”
47. **5th Transplantation Conference, Immunology Research Group,** Emerald Lake, Alberta, Canada (2003)
    * 1. “Post-Transplant Monitoring in Renal Transplantation”
48. **7th Banff Allograft Pathology Conference,** Aberdeen, Scotland (2003)
    * 1. "Anti-HLA Antibody Importance of Memory vs. De Novo Responses in Renal Transplants"
49. **Canadian Society of Nephrology,** St. John's, Newfoundland, Canada (2003)
    * 1. "Early Detection of Rejection - The Renaissance of Urinalysis"
50. **The Canadian Society of Transplantation,** Lake Louise, Alberta, Canada (2003)
    * 1. "The Detection of Immunologic Memory Pre-Transplant"
51. **17th Annual Advanced HLA Technical Workshop,** Honolulu, Hawaii, USA (2003)
    * 1. "The Importance of Monitoring HLA Class II Antibodies"
52. **American Society of Nephrology, Symposium,** Philadelphia, Pennsylvania, USA (2002)
    * 1. "Urine Spectroscopy"
53. **American Society of Nephrology, Post Graduate Education,** Philadelphia, Pennsylvania, USA (2002)
    * 1. "Surrogate Markers for Allograft Rejection"
54. **Canadian Blood Services/Hospital Blood Bank Joint Meeting,** Winnipeg, Manitoba, Canada (2002)
    * 1. "The Importance of Immunologic Memory in Transplantation"
55. **American Transplant Congress, Annual Meeting, Luncheon Workshop,** Washington, USA (2002)
    * 1. "Novel Approaches to Monitor Allograft Rejection"
56. **International Society for Laboratory Hematology,** Banff Springs, Alberta, Canada (2002)
    * 1. "Flow Cytometric Cross Matching for BMT"
57. **The European Group for Blood and Marrow Transplantation,** Montreux, Switzerland (2002)
    * 1. "Transplant rejection: a current perspective"
58. **Canadian Society of Transplantation,** Annual Meeting, Mont-Tremblant, Quebec, Canada (2002)
    * 1. "New approaches to monitoring patients post transplant"
      2. "Update on Transplant HLA"
59. **Austrotransplant Meeting,** Going, Austria (2001)
    * 1. "Novel Non-Invasive Diagnosis of Acute Rejection"
60. **AST/ASTS Consensus Endpoints for Clinical Trials on Late Allograft Failure,** Washington, DC, USA (2001)
    * 1. "Protocol Biopsies: Are they useful in providing surrogate markers?"
61. **2nd Canadian Transplant Forum: Long-Term Immunosuppressive Management,** Ottawa, ON, Canada (2001)
    * 1. "Non-Invasive Diagnosis and Subsequent Monitoring of Renal Allograft
      2. Rejection Using Urine NMR Spectra"
62. **American Society of Nephrology Annual Meeting, Co-Chair, PGE Course,** San Francisco, USA (2001)
    * 1. "Tissue Typing and Cross-Matching"
63. **European Transplant Society,** Vienna, Austria (2001)
    * 1. “Role of Subclinical Rejection in the Pathogenesis of Chronic Rejection”
64. **American Transplant Society, Annual Meeting,** **Luncheon Workshop** Chicago, USA (2001)
    * 1. “Novel Approaches to Monitor Allograft Rejection”
65. **American Transplant Society , Post-Graduate Course,** Chicago, USA (2001)
    * 1. “Mechanisms of Allograft Rejection and Strategies for Monitoring Rejection”
66. **Canadian Society of Nephrology Annual Meeting,** Vancouver,BC,Canada (2001)
    * 1. “Cellular Immune Networks in Transplantation”
67. **“On the Edge” Invited Lecture, University of Manitoba,** Winnipeg, MB, Canada (2001)
    * 1. “Diagnosing Transplant Rejection: Beyond the Biopsy”
68. **9 Symposium: Interdisziplinare Studiengruppe Nierentransplantation im Kindes- und Jugendalter,** Hinterzarten, Germany (2000)
    * 1. “Subclinical rejection: A Predictor of Chronic rejection?”
69. **1st Canadian Transplant Forum: Chronic Allograft Rejection** Montreal, PQ, Canada (2000)
    * 1. "Chronic rejection: Phenotype & Immune Risk."
70. **American Society of Nephrology Annual Meeting PGE Course**, Toronto, Canada (2000)
    * 1. “Novel Approaches to Studying Alloimmune Responses and Allograft Rejection in Humans”
71. **One Lambda Workshop,** Jamaica (2000)
    * 1. “Cytokine Genotyping and Early Inflammation Post-Transplant”
72. **American Society of Nephrology Annual Meeting**, Miami, USA (1999)
    * 1. “Early Detection of Allograft Inflammation”
73. **5th ISN Banff Conference of Allograft Pathology**, Banff, Canada (1999)
    * 1. “Alternatives to Protocol Biopsies in the Kidney”
74. **Sangstat Symposia**, Current and Future Trends in Induction Therapy. Toronto, Canada (1998)
    * 1. “Renal Induction Therapy: Do we need it?”
75. **Swiss Nephrology Society**, Basel, Switzerland (1997)
    * 1. “Early Risk Factors of Declining Renal Function”
      2. “Mechanisms and Future Strategies to Prevent Chronic Rejection”
76. **International Society of Nephrology (ISN)**, Sydney, Australia (1997)
    * 1. “Role of Cytokines in Tolerance”
77. **4th ISN Banff Conference of Allograft Pathology**, Banff, Canada (1997)
    * 1. “Early Risk Factors of Diminished Renal Function 2 years Post Transplant”
78. **American Society of Transplant Surgeons Post-Graduate Course**, Dallas, USA (1996)
    * 1. “Tolerance and Rejection-Lessons from Transgenes and Knock-Outs”

***Administrative Activities***

**Vice Dean (Research), Rady Faculty of Health Science, University of Manitoba (2010 to present)**

* **Scope:** Administrative leadership for research in the Faculty of Medicine.
* **Initiatives:**
  + Strategic Research Plan 2012 – 2017, renewed plan to 2020
  + Develop biomedical and clinical research platforms for the University of Manitoba
  + Foster research clusters/teams within the Faculty of Medicine

**Medical Director, Transplant Manitoba (2014 to present)**

* **Scope:** Medical-Administrative leadership for the provincial organ transplant programs and development of a TQI program to comply with Health Canada regulations.
* **Initiatives:**
  + Business Plan for Transplant Manitoba for the developed of a integrated out-patient clinical unit for kidney, liver and lung transplant recipients **pre and post-transplant care** (Shared Health funded 2018)
  + Developed an Alternative Funding Plan (AFP) to support adult kidney transplant physician manpower (Shared Health and Manitoba Health funded 2018)

**Medical Consultant (Transplant), Organ and Tissue Division, Canadian Blood Services (2009 to present)**

* **Scope:** Medical-Administrative leadership to establish National Organ Registries (Living Donor Exchange, Highly Sensitized, Urgent Status for Liver, Lung and Heart) as well as a National Strategic Plan in Organ and Tissue Donation and Transplantation.
* **Initiatives:**
  + Launched in Mar 2014 the CBS National Highly Sensitized (HSP) Registry
  + Launched in Feb 2009 the CBS National Kidney Paired Donation (KPD) Registry
  + Chair, CBS Organ Expert Committee, National Strategic Plan – working with consultants from Palladium Inc. creating a National Strategy Map and Balanced Scorecards for organ donation and transplantation.
  + Established National Organ Donation Collaborative (Institute for Health Care Improvement (IHI) Model)

**Medical Director, Transplant Manitoba – Gift of Life Program (2005 to 2010)**

* **Scope:** Medical-Administrative leadership for the provincial organ procurement organization and development of a TQI program to comply with Health Canada regulations.
* **Initiatives:**
  + Proposal for the Manitoba Adult Renal Transplant Programand the Manitoba Organ Donor Organization at the Health Sciences Centre (WRHA funded Phase I in 2005) – co-written with Dr. D. Rush
  + Improving Access to Transplantation for Manitobans (WRHA funded Phase II in 2007 and Phase III in 2009) – co-written with Dr. D. Rush and Ms. Jan Currie

**Medical Consultant, Transplant Immunology Laboratory, Diagnostic Services of Manitoba (1998 to present)**

* **Scope:** Medical-Scientific leadership for the Transplant Immunology Laboratory
* **Initiatives:** 
  + Retooling the transplant laboratory for molecular and flow based diagnostics (WRHA funded 1999)

**Medical Director, Platelet Immunology Laboratory, Canadian Blood Services (2001 to present)**

* **Scope:** Medical-Scientific leadership for the Platelet Immunology Laboratory
* **Initiatives:**
  + Restructuring HLA Typing Services for the Unrelated Bone Marrow Registry (UBMDR) (CBS funded 2002) – co-written with Beverly Campbell
  + Development of a National Platelet Donor Registry (CBS funded 2002) - Dr. H. Hume Sponsor
  + Restructuring of the National TRALI testing infrastructure (CBS funded 2007) - Dr. M. Goldman Sponsor

**Medical Director, Immunology Laboratory Sub-Program, Winnipeg Regional Health Authority (1999 – 2004)**

* **Scope:** Medical-Administrative leadership for the Immunology Division of Laboratory Medicine overseeing the Immunology Laboratory (Health Sciences Centre site), Immunology Laboratory (St Boniface Hospital site) and Transplant Immunology Laboratory.
* **Initiatives:**
  + Creating a Provincial Laboratory System (Manitoba Government funded 2002 with establishment of Diagnostics Services of Manitoba) – responsible for development of immunodiagnostics section.

***Health Policy Development***

**Canadian Council for Donation and Transplantation (CCDT)**

“Medical Management to Optimize Organ Donor Potential” (Oct 2004)

**Role:** Member of Forum Recommendation Group (FRG) and writing committee

“Assessment and Management of Immune Risk in Transplantation” (Jan 2005)

**Role:** Chair

Task Force Report on potential for Living Donor Paired Exchange and Highly Sensitized Registries (Jan 2006)

**Role:** Co-Chair with Dr. E. Cole

“Kidney Allocation in Canada: a Canadian Forum” (Feb 2007)

**Role:** Member of Steering Committee, Forum Recommendation Group and writing committee

Lab Sub-Committee to develop Standards for HLA testing in support of National Registries (Jan 2006)

**Role:** Co-Chair with Dr. T. Campbell

**Accreditation Canada (Agrément Canada)**

“Organ and Tissue Donation and Transplant Advisory Committee” (2008-2010)

**Role:** Committee member developing accreditation standards in organ and tissue donation and transplantation for hospital Emergency Departments, Intensive Care Units, and Organ Transplantation Units.

**Manitoba**

“Kidney Allocation in Manitoba” (Oct 2007 to present)

**Role:** Lead policy writer and presenter to health professionals, government and public focus groups

***Industry Advisory Boards:***

Active:

* **CSL Behring/**Vitaeris – **IMAGINE Trial** – Chair, Study Protocol; Medical Consultant, HLA antibody review
* **Renalytix AI**
* **Terasaki Innovation Center, Inc.**
* **Azoth Immune Medicines, Inc.**
* **Astellas** –Asia Division

Last 5 Years:

* 2021: **Novartis**
* 2020: **ITB Med LLC**
* 2020: **Palidin Labs, Inc.**
* 2019: **Viela Bio**
* 2017: **Astellas** –US Division
* 2016: **GSK**